3c4c › Citations

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.

Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K, Li L, Smalley KS, Fong D, Zhu YL, Marimuthu A, Nguyen H, Lam B, Liu J, Cheung I, Rice J, Suzuki Y, Luu C, Settachatgul C, Shellooe R, Cantwell J, Kim SH, Schlessinger J, Zhang KY, West BL, Powell B, Habets G, Zhang C, Ibrahim PN, Hirth P, Artis DR, Herlyn M, Bollag G
Proc Natl Acad Sci U S A 105 3041-6 (2008)
Related entries: 3c4e, 3c4f, 4fk3

Cited: 779 times
EuropePMC logo PMID: 18287029

Abstract

BRAF(V600E) is the most frequent oncogenic protein kinase mutation known. Furthermore, inhibitors targeting "active" protein kinases have demonstrated significant utility in the therapeutic repertoire against cancer. Therefore, we pursued the development of specific kinase inhibitors targeting B-Raf, and the V600E allele in particular. By using a structure-guided discovery approach, a potent and selective inhibitor of active B-Raf has been discovered. PLX4720, a 7-azaindole derivative that inhibits B-Raf(V600E) with an IC(50) of 13 nM, defines a class of kinase inhibitor with marked selectivity in both biochemical and cellular assays. PLX4720 preferentially inhibits the active B-Raf(V600E) kinase compared with a broad spectrum of other kinases, and potent cytotoxic effects are also exclusive to cells bearing the V600E allele. Consistent with the high degree of selectivity, ERK phosphorylation is potently inhibited by PLX4720 in B-Raf(V600E)-bearing tumor cell lines but not in cells lacking oncogenic B-Raf. In melanoma models, PLX4720 induces cell cycle arrest and apoptosis exclusively in B-Raf(V600E)-positive cells. In B-Raf(V600E)-dependent tumor xenograft models, orally dosed PLX4720 causes significant tumor growth delays, including tumor regressions, without evidence of toxicity. The work described here represents the entire discovery process, from initial identification through structural and biological studies in animal models to a promising therapeutic for testing in cancer patients bearing B-Raf(V600E)-driven tumors.

Reviews - 3c4c mentioned but not cited (3)

  1. Lessons from Hot Spot Analysis for Fragment-Based Drug Discovery. Hall DR, Kozakov D, Whitty A, Vajda S. Trends Pharmacol Sci 36 724-736 (2015)
  2. The azaindole framework in the design of kinase inhibitors. Mérour JY, Buron F, Plé K, Bonnet P, Routier S. Molecules 19 19935-19979 (2014)
  3. Impact of the Protein Data Bank on antineoplastic approvals. Westbrook JD, Soskind R, Hudson BP, Burley SK. Drug Discov Today 25 837-850 (2020)

Articles - 3c4c mentioned but not cited (28)

  1. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K. Nature 467 596-599 (2010)
  2. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K, Li L, Smalley KS, Fong D, Zhu YL, Marimuthu A, Nguyen H, Lam B, Liu J, Cheung I, Rice J, Suzuki Y, Luu C, Settachatgul C, Shellooe R, Cantwell J, Kim SH, Schlessinger J, Zhang KY, West BL, Powell B, Habets G, Zhang C, Ibrahim PN, Hirth P, Artis DR, Herlyn M, Bollag G. Proc Natl Acad Sci U S A 105 3041-3046 (2008)
  3. PEBP1 Wardens Ferroptosis by Enabling Lipoxygenase Generation of Lipid Death Signals. Wenzel SE, Tyurina YY, Zhao J, St Croix CM, Dar HH, Mao G, Tyurin VA, Anthonymuthu TS, Kapralov AA, Amoscato AA, Mikulska-Ruminska K, Shrivastava IH, Kenny EM, Yang Q, Rosenbaum JC, Sparvero LJ, Emlet DR, Wen X, Minami Y, Qu F, Watkins SC, Holman TR, VanDemark AP, Kellum JA, Bahar I, Bayır H, Kagan VE. Cell 171 628-641.e26 (2017)
  4. Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Lavoie H, Thevakumaran N, Gavory G, Li JJ, Padeganeh A, Guiral S, Duchaine J, Mao DY, Bouvier M, Sicheri F, Therrien M. Nat Chem Biol 9 428-436 (2013)
  5. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors. Vijayan RS, He P, Modi V, Duong-Ly KC, Ma H, Peterson JR, Dunbrack RL, Levy RM. J Med Chem 58 466-479 (2015)
  6. Is It Reliable to Take the Molecular Docking Top Scoring Position as the Best Solution without Considering Available Structural Data? Ramírez D, Caballero J. Molecules 23 (2018)
  7. Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling. Dhawan NS, Scopton AP, Dar AC. Nature 537 112-116 (2016)
  8. Identification of a novel family of BRAF(V600E) inhibitors. Qin J, Xie P, Ventocilla C, Zhou G, Vultur A, Chen Q, Liu Q, Herlyn M, Winkler J, Marmorstein R. J Med Chem 55 5220-5230 (2012)
  9. Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain. Wagenaar TR, Ma L, Roscoe B, Park SM, Bolon DN, Green MR. Pigment Cell Melanoma Res 27 124-133 (2014)
  10. Phosphorylation of RAF Kinase Dimers Drives Conformational Changes that Facilitate Transactivation. Jambrina PG, Rauch N, Pilkington R, Rybakova K, Nguyen LK, Kholodenko BN, Buchete NV, Kolch W, Rosta E. Angew Chem Int Ed Engl 55 983-986 (2016)
  11. Prediction of molecular targets of cancer preventing flavonoid compounds using computational methods. Chen H, Yao K, Nadas J, Bode AM, Malakhova M, Oi N, Li H, Lubet RA, Dong Z. PLoS One 7 e38261 (2012)
  12. DockoMatic 2.0: high throughput inverse virtual screening and homology modeling. Bullock C, Cornia N, Jacob R, Remm A, Peavey T, Weekes K, Mallory C, Oxford JT, McDougal OM, Andersen TL. J Chem Inf Model 53 2161-2170 (2013)
  13. Structure-functional prediction and analysis of cancer mutation effects in protein kinases. Dixit A, Verkhivker GM. Comput Math Methods Med 2014 653487 (2014)
  14. Expression of the essential Kinase PfCDPK1 from Plasmodium falciparum in Toxoplasma gondii facilitates the discovery of novel antimalarial drugs. Gaji RY, Checkley L, Reese ML, Ferdig MT, Arrizabalaga G. Antimicrob Agents Chemother 58 2598-2607 (2014)
  15. Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways. Tse A, Verkhivker GM. PLoS One 11 e0166583 (2016)
  16. Repositioning organohalogen drugs: a case study for identification of potent B-Raf V600E inhibitors via docking and bioassay. Li Y, Guo B, Xu Z, Li B, Cai T, Zhang X, Yu Y, Wang H, Shi J, Zhu W. Sci Rep 6 31074 (2016)
  17. Identification of Druggable Kinase Target Conformations Using Markov Model Metastable States Analysis of apo-Abl. Paul F, Meng Y, Roux B. J Chem Theory Comput 16 1896-1912 (2020)
  18. Molecular modeling, dynamics simulations, and binding efficiency of berberine derivatives: A new group of RAF inhibitors for cancer treatment. Jabbarzadeh Kaboli P, Ismail P, Ling KH. PLoS One 13 e0193941 (2018)
  19. Privileged Structures and Polypharmacology within and between Protein Families. Meyers J, Chessum NEA, Ali S, Mok NY, Wilding B, Pasqua AE, Rowlands M, Tucker MJ, Evans LE, Rye CS, O'Fee L, Le Bihan YV, Burke R, Carter M, Workman P, Blagg J, Brown N, van Montfort RLM, Jones K, Cheeseman MD. ACS Med Chem Lett 9 1199-1204 (2018)
  20. Recurrent somatic BRAF insertion (p.V504_R506dup): a tumor marker and a potential therapeutic target in pilocytic astrocytoma. Khater F, Langlois S, Cassart P, Roy AM, Lajoie M, Healy J, Richer C, St-Onge P, Piché N, Perreault S, Cellot S, Marzouki M, Jabado N, Sinnett D. Oncogene 38 2994-3002 (2019)
  21. An integrative approach to develop computational pipeline for drug-target interaction network analysis. Bansal A, Srivastava PA, Singh TR. Sci Rep 8 10238 (2018)
  22. Inactivation of RIP3 kinase sensitizes to 15LOX/PEBP1-mediated ferroptotic death. Lamade AM, Wu L, Dar HH, Mentrup HL, Shrivastava IH, Epperly MW, St Croix CM, Tyurina YY, Anthonymuthu TS, Yang Q, Kapralov AA, Huang Z, Mao G, Amoscato AA, Hier ZE, Artyukhova MA, Shurin G, Rosenbaum JC, Gough PJ, Bertin J, VanDemark AP, Watkins SC, Mollen KP, Bahar I, Greenberger JS, Kagan VE, Whalen MJ, Bayır H. Redox Biol 50 102232 (2022)
  23. Cloning, expression, purification and preliminary X-ray analysis of the protein kinase domain of constitutive triple response 1 (CTR1) from Arabidopsis thaliana. Mayerhofer H, Mueller-Dieckmann C, Mueller-Dieckmann J. Acta Crystallogr Sect F Struct Biol Cryst Commun 67 117-120 (2011)
  24. In Silico Identification of Multi-Target Ligands as Promising Hit Compounds for Neurodegenerative Diseases Drug Development. Alov P, Stoimenov H, Lessigiarska I, Pencheva T, Tzvetkov NT, Pajeva I, Tsakovska I. Int J Mol Sci 23 13650 (2022)
  25. Network Pharmacology and Experimental Validation to Explore the Mechanism of Qing-Jin-Hua-Tan-Decoction Against Acute Lung Injury. Xiao S, Liu L, Sun Z, Liu X, Xu J, Guo Z, Yin X, Liao F, Xu J, You Y, Zhang T. Front Pharmacol 13 891889 (2022)
  26. Structural and dynamic determinants for highly selective RET kinase inhibition reveal cryptic druggability. Shehata MA, Contreras J, Martín-Hurtado A, Froux A, Mohamed HT, El-Sherif AA, Plaza-Menacho I. J Adv Res 45 87-100 (2023)
  27. Synthesis, molecular modeling, and biological evaluation of novel imatinib derivatives as anticancer agents. Günay F, Balta S, Ng YY, Ulucan Ö, Turgut Z, Günkara ÖT. Turk J Chem 46 86-102 (2022)
  28. The protein kinase promiscuities in the cancer-preventive mechanisms of NSAIDs. Norvaisas P, Chan D, Yokoi K, Dave B, Ziemys A. Eur J Cancer Prev 25 77-84 (2016)


Reviews citing this publication (266)

  1. New driver mutations in non-small-cell lung cancer. Pao W, Girard N. Lancet Oncol 12 175-180 (2011)
  2. Targeting RAS-ERK signalling in cancer: promises and challenges. Samatar AA, Poulikakos PI. Nat Rev Drug Discov 13 928-942 (2014)
  3. Development of PI3K inhibitors: lessons learned from early clinical trials. Rodon J, Dienstmann R, Serra V, Tabernero J. Nat Rev Clin Oncol 10 143-153 (2013)
  4. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Holderfield M, Deuker MM, McCormick F, McMahon M. Nat Rev Cancer 14 455-467 (2014)
  5. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Milella M, Tafuri A, Bonati A, Evangelisti C, Cocco L, Martelli AM, McCubrey JA. Oncotarget 2 135-164 (2011)
  6. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. Lancet Oncol 12 594-603 (2011)
  7. Vemurafenib: the first drug approved for BRAF-mutant cancer. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P. Nat Rev Drug Discov 11 873-886 (2012)
  8. The role of ligand efficiency metrics in drug discovery. Hopkins AL, Keserü GM, Leeson PD, Rees DC, Reynolds CH. Nat Rev Drug Discov 13 105-121 (2014)
  9. Melanoma: from mutations to medicine. Tsao H, Chin L, Garraway LA, Fisher DE. Genes Dev 26 1131-1155 (2012)
  10. Tumour cell survival signalling by the ERK1/2 pathway. Balmanno K, Cook SJ. Cell Death Differ 16 368-377 (2009)
  11. Targeting the RAF-MEK-ERK pathway in cancer therapy. Montagut C, Settleman J. Cancer Lett 283 125-134 (2009)
  12. Regulation of RAF protein kinases in ERK signalling. Lavoie H, Therrien M. Nat Rev Mol Cell Biol 16 281-298 (2015)
  13. From genes to drugs: targeted strategies for melanoma. Flaherty KT, Hodi FS, Fisher DE. Nat Rev Cancer 12 349-361 (2012)
  14. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Hoelder S, Clarke PA, Workman P. Mol Oncol 6 155-176 (2012)
  15. The structural basis for control of eukaryotic protein kinases. Endicott JA, Noble ME, Johnson LN. Annu Rev Biochem 81 587-613 (2012)
  16. Lung cancer: Biology and treatment options. Lemjabbar-Alaoui H, Hassan OU, Yang YW, Buchanan P. Biochim Biophys Acta 1856 189-210 (2015)
  17. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, Mazzarino MC, Fagone P, Nicoletti F, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Chiarini F, Evangelisti C, Cocco L, Martelli AM. Oncotarget 3 1068-1111 (2012)
  18. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Jänne PA, Gray N, Settleman J. Nat Rev Drug Discov 8 709-723 (2009)
  19. A historical overview of protein kinases and their targeted small molecule inhibitors. Roskoski R. Pharmacol Res 100 1-23 (2015)
  20. Raf kinases in cancer-roles and therapeutic opportunities. Maurer G, Tarkowski B, Baccarini M. Oncogene 30 3477-3488 (2011)
  21. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery. Ruggeri BA, Camp F, Miknyoczki S. Biochem Pharmacol 87 150-161 (2014)
  22. The molecular pathology of cancer. Harris TJ, McCormick F. Nat Rev Clin Oncol 7 251-265 (2010)
  23. Which drug, and when, for patients with BRAF-mutant melanoma? Jang S, Atkins MB. Lancet Oncol 14 e60-9 (2013)
  24. New perspectives for targeting RAF kinase in human cancer. Karoulia Z, Gavathiotis E, Poulikakos PI. Nat Rev Cancer 17 676-691 (2017)
  25. Mismatch repair deficient colorectal cancer in the era of personalized treatment. Hewish M, Lord CJ, Martin SA, Cunningham D, Ashworth A. Nat Rev Clin Oncol 7 197-208 (2010)
  26. Clinical implications of the cancer genome. Macconaill LE, Garraway LA. J Clin Oncol 28 5219-5228 (2010)
  27. BRAF signaling and targeted therapies in melanoma. Dhomen N, Marais R. Hematol Oncol Clin North Am 23 529-45, ix (2009)
  28. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Pratilas CA, Solit DB. Clin Cancer Res 16 3329-3334 (2010)
  29. Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Gibney GT, Messina JL, Fedorenko IV, Sondak VK, Smalley KS. Nat Rev Clin Oncol 10 390-399 (2013)
  30. Personalised cancer medicine. Jackson SE, Chester JD. Int J Cancer 137 262-266 (2015)
  31. Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Inamdar GS, Madhunapantula SV, Robertson GP. Biochem Pharmacol 80 624-637 (2010)
  32. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Ihle NT, Powis G. Mol Cancer Ther 8 1-9 (2009)
  33. Targeted cancer therapies in the twenty-first century: lessons from imatinib. Stegmeier F, Warmuth M, Sellers WR, Dorsch M. Clin Pharmacol Ther 87 543-552 (2010)
  34. Structural biology in fragment-based drug design. Murray CW, Blundell TL. Curr Opin Struct Biol 20 497-507 (2010)
  35. Ten things you should know about protein kinases: IUPHAR Review 14. Fabbro D, Cowan-Jacob SW, Moebitz H. Br J Pharmacol 172 2675-2700 (2015)
  36. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. McDermott U, Settleman J. J Clin Oncol 27 5650-5659 (2009)
  37. Targeting protein-protein interaction by small molecules. Jin L, Wang W, Fang G. Annu Rev Pharmacol Toxicol 54 435-456 (2014)
  38. Targeting apoptosis in cancer therapy. Carneiro BA, El-Deiry WS. Nat Rev Clin Oncol 17 395-417 (2020)
  39. KRAS and BRAF: drug targets and predictive biomarkers. Vakiani E, Solit DB. J Pathol 223 219-229 (2011)
  40. Chloroquine and hydroxychloroquine for cancer therapy. Manic G, Obrist F, Kroemer G, Vitale I, Galluzzi L. Mol Cell Oncol 1 e29911 (2014)
  41. Targets of Raf in tumorigenesis. Niault TS, Baccarini M. Carcinogenesis 31 1165-1174 (2010)
  42. Analysis of the genome to personalize therapy for melanoma. Davies MA, Samuels Y. Oncogene 29 5545-5555 (2010)
  43. Transforming fragments into candidates: small becomes big in medicinal chemistry. de Kloe GE, Bailey D, Leurs R, de Esch IJ. Drug Discov Today 14 630-646 (2009)
  44. A new era: melanoma genetics and therapeutics. Ko JM, Fisher DE. J Pathol 223 241-250 (2011)
  45. BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Nucera C, Lawler J, Parangi S. Cancer Res 71 2417-2422 (2011)
  46. Targeting the RAS oncogene. Takashima A, Faller DV. Expert Opin Ther Targets 17 507-531 (2013)
  47. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway. Tidyman WE, Rauen KA. Expert Rev Mol Med 10 e37 (2008)
  48. Targeted therapies: how personal should we go? Martini M, Vecchione L, Siena S, Tejpar S, Bardelli A. Nat Rev Clin Oncol 9 87-97 (2011)
  49. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. Kakadia S, Yarlagadda N, Awad R, Kundranda M, Niu J, Naraev B, Mina L, Dragovich T, Gimbel M, Mahmoud F. Onco Targets Ther 11 7095-7107 (2018)
  50. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Lim SY, Menzies AM, Rizos H. Cancer 123 2118-2129 (2017)
  51. Emerging insights into resistance to BRAF inhibitors in melanoma. Bucheit AD, Davies MA. Biochem Pharmacol 87 381-389 (2014)
  52. Treatment implications of the emerging molecular classification system for melanoma. Romano E, Schwartz GK, Chapman PB, Wolchock JD, Carvajal RD. Lancet Oncol 12 913-922 (2011)
  53. Small molecules and targeted therapies in distant metastatic disease. Hersey P, Bastholt L, Chiarion-Sileni V, Cinat G, Dummer R, Eggermont AM, Espinosa E, Hauschild A, Quirt I, Robert C, Schadendorf D. Ann Oncol 20 Suppl 6 vi35-40 (2009)
  54. Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies. Medves S, Demoulin JB. J Cell Mol Med 16 237-248 (2012)
  55. Targeting BRAF in advanced melanoma: a first step toward manageable disease. Vultur A, Villanueva J, Herlyn M. Clin Cancer Res 17 1658-1663 (2011)
  56. Linking somatic genetic alterations in cancer to therapeutics. Stuart D, Sellers WR. Curr Opin Cell Biol 21 304-310 (2009)
  57. Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. Mandal R, Becker S, Strebhardt K. Oncogene 35 2547-2561 (2016)
  58. Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Kudchadkar R, Paraiso KH, Smalley KS. Cancer J 18 124-131 (2012)
  59. Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science. Hochberg FH, Atai NA, Gonda D, Hughes MS, Mawejje B, Balaj L, Carter RS. Expert Rev Mol Diagn 14 439-452 (2014)
  60. Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma. Luke JJ, Hodi FS. Oncologist 18 717-725 (2013)
  61. BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oikonomou E, Koustas E, Goulielmaki M, Pintzas A. Oncotarget 5 11752-11777 (2014)
  62. The evolving role of radiation therapy in the management of malignant melanoma. Khan N, Khan MK, Almasan A, Singh AD, Macklis R. Int J Radiat Oncol Biol Phys 80 645-654 (2011)
  63. A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets. Uitdehaag JC, Verkaar F, Alwan H, de Man J, Buijsman RC, Zaman GJ. Br J Pharmacol 166 858-876 (2012)
  64. Histone acetyltransferases: Rising ancient counterparts to protein kinases. Yuan H, Marmorstein R. Biopolymers 99 98-111 (2013)
  65. Modeling Melanoma In Vitro and In Vivo. Beaumont KA, Mohana-Kumaran N, Haass NK. Healthcare (Basel) 2 27-46 (2013)
  66. Targeting MAPK pathway in melanoma therapy. Cheng Y, Zhang G, Li G. Cancer Metastasis Rev 32 567-584 (2013)
  67. Targeting the RAS pathway in melanoma. Ji Z, Flaherty KT, Tsao H. Trends Mol Med 18 27-35 (2012)
  68. BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications. Sclafani F, Gullo G, Sheahan K, Crown J. Crit Rev Oncol Hematol 87 55-68 (2013)
  69. Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy. Degirmenci U, Wang M, Hu J. Cells 9 (2020)
  70. Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies. Sharma A, Shah SR, Illum H, Dowell J. Drugs 72 2207-2222 (2012)
  71. Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas. Penman CL, Faulkner C, Lowis SP, Kurian KM. Front Oncol 5 54 (2015)
  72. Drug discovery and the human kinome: recent trends. Eglen R, Reisine T. Pharmacol Ther 130 144-156 (2011)
  73. BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis. Chen D, Zhang LQ, Huang JF, Liu K, Chuai ZR, Yang Z, Wang YX, Shi DC, Liu Q, Huang Q, Fu WL. PLoS One 9 e101354 (2014)
  74. Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy. Baik CS, Myall NJ, Wakelee HA. Oncologist 22 786-796 (2017)
  75. Cancer therapy based on oncogene addiction. McCormick F. J Surg Oncol 103 464-467 (2011)
  76. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma. Kim A, Cohen MS. Expert Opin Drug Discov 11 907-916 (2016)
  77. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors. Grimaldi AM, Simeone E, Festino L, Vanella V, Strudel M, Ascierto PA. Am J Clin Dermatol 18 745-754 (2017)
  78. Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Strickland LR, Pal HC, Elmets CA, Afaq F. Cancer Lett 359 20-35 (2015)
  79. Therapy for metastatic melanoma: an overview and update. Boyle GM. Expert Rev Anticancer Ther 11 725-737 (2011)
  80. MAPK kinase signalling dynamics regulate cell fate decisions and drug resistance. Rauch N, Rukhlenko OS, Kolch W, Kholodenko BN. Curr Opin Struct Biol 41 151-158 (2016)
  81. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma. Wang AX, Qi XY. IUBMB Life 65 748-758 (2013)
  82. Targeting the Raf kinases in human cancer: the Raf dimer dilemma. Durrant DE, Morrison DK. Br J Cancer 118 3-8 (2018)
  83. Emerging targeted therapies for melanoma treatment (review). Russo A, Ficili B, Candido S, Pezzino FM, Guarneri C, Biondi A, Travali S, McCubrey JA, Spandidos DA, Libra M. Int J Oncol 45 516-524 (2014)
  84. Targeting the ERK Signaling Pathway in Melanoma. Savoia P, Fava P, Casoni F, Cremona O. Int J Mol Sci 20 (2019)
  85. Update on the targeted therapy of melanoma. Johnson DB, Sosman JA. Curr Treat Options Oncol 14 280-292 (2013)
  86. Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity. Hertz DL, McLeod HL. J Hum Genet 58 346-352 (2013)
  87. Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges. Millet A, Martin AR, Ronco C, Ronco C, Rocchi S, Benhida R. Med Res Rev 37 98-148 (2017)
  88. No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients. Girotti MR, Saturno G, Lorigan P, Marais R. Mol Oncol 8 1140-1158 (2014)
  89. Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Nucera C, Goldfarb M, Hodin R, Parangi S. Biochim Biophys Acta 1795 152-161 (2009)
  90. Signal control through Raf: in sickness and in health. Osborne JK, Zaganjor E, Cobb MH. Cell Res 22 14-22 (2012)
  91. Structure based approaches for targeting non-coding RNAs with small molecules. Shortridge MD, Varani G. Curr Opin Struct Biol 30 79-88 (2015)
  92. BRAF inhibitors: experience in thyroid cancer and general review of toxicity. Cabanillas ME, Patel A, Danysh BP, Dadu R, Kopetz S, Falchook G. Horm Cancer 6 21-36 (2015)
  93. Bioinformatics and variability in drug response: a protein structural perspective. Lahti JL, Tang GW, Capriotti E, Liu T, Altman RB. J R Soc Interface 9 1409-1437 (2012)
  94. Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations. Ho HK, Yeo AH, Kang TS, Chua BT. Drug Discov Today 19 51-62 (2014)
  95. Small-molecule inhibitors of the ERK signaling pathway: Towards novel anticancer therapeutics. Yap JL, Worlikar S, MacKerell AD, Shapiro P, Fletcher S. ChemMedChem 6 38-48 (2011)
  96. New strategies in melanoma: molecular testing in advanced disease. Woodman SE, Lazar AJ, Aldape KD, Davies MA. Clin Cancer Res 18 1195-1200 (2012)
  97. Strategies to design clinical studies to identify predictive biomarkers in cancer research. Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I. Cancer Treat Rev 53 79-97 (2017)
  98. BRAF and MEK inhibition in melanoma. Dossett LA, Kudchadkar RR, Zager JS. Expert Opin Drug Saf 14 559-570 (2015)
  99. Recent progress on MAP kinase pathway inhibitors. Uehling DE, Harris PA. Bioorg Med Chem Lett 25 4047-4056 (2015)
  100. Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. Dent P, Curiel DT, Fisher PB, Grant S. Drug Resist Updat 12 65-73 (2009)
  101. Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis. Yauch RL, Settleman J. Curr Opin Genet Dev 22 45-49 (2012)
  102. A brief history of melanoma: from mummies to mutations. Rebecca VW, Sondak VK, Smalley KS. Melanoma Res 22 114-122 (2012)
  103. Combination of targeted therapy and immunotherapy in melanoma. Blank CU, Hooijkaas AI, Haanen JB, Schumacher TN. Cancer Immunol Immunother 60 1359-1371 (2011)
  104. Small molecule inhibitors of BRAF in clinical trials. Zambon A, Niculescu-Duvaz I, Niculescu-Duvaz D, Marais R, Springer CJ. Bioorg Med Chem Lett 22 789-792 (2012)
  105. Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. Angelbello AJ, Chen JL, Childs-Disney JL, Zhang P, Wang ZF, Disney MD. Chem Rev 118 1599-1663 (2018)
  106. B-RAF inhibitors: an evolving role in the therapy of malignant melanoma. Shepherd C, Puzanov I, Sosman JA. Curr Oncol Rep 12 146-152 (2010)
  107. Oncogene-induced senescence as a new mechanism of disease: the paradigm of erdheim-chester disease. Cavalli G, Biavasco R, Borgiani B, Dagna L. Front Immunol 5 281 (2014)
  108. Recent developments in the medical and surgical treatment of melanoma. Saranga-Perry V, Ambe C, Zager JS, Kudchadkar RR. CA Cancer J Clin 64 171-185 (2014)
  109. Structure-based and fragment-based GPCR drug discovery. Andrews SP, Brown GA, Christopher JA. ChemMedChem 9 256-275 (2014)
  110. Evaluating biomarkers in melanoma. Karagiannis P, Fittall M, Karagiannis SN. Front Oncol 4 383 (2014)
  111. Structural biology contributions to tyrosine kinase drug discovery. Cowan-Jacob SW, Möbitz H, Fabbro D. Curr Opin Cell Biol 21 280-287 (2009)
  112. Targeting Oncogenic BRAF: Past, Present, and Future. Zaman A, Wu W, Bivona TG. Cancers (Basel) 11 (2019)
  113. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. Yuan J, Dong X, Yap J, Hu J. J Hematol Oncol 13 113 (2020)
  114. BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors. Sánchez-Torres JM, Viteri S, Molina MA, Rosell R. Transl Lung Cancer Res 2 244-250 (2013)
  115. From bench to bedside: lessons learned in translating preclinical studies in cancer drug development. Lieu CH, Tan AC, Leong S, Diamond JR, Eckhardt SG. J Natl Cancer Inst 105 1441-1456 (2013)
  116. The role of MEK inhibitors in the treatment of metastatic melanoma. Grimaldi AM, Simeone E, Ascierto PA. Curr Opin Oncol 26 196-203 (2014)
  117. A comprehensive review of protein kinase inhibitors for cancer therapy. Kannaiyan R, Mahadevan D. Expert Rev Anticancer Ther 18 1249-1270 (2018)
  118. It takes two to tango--signalling by dimeric Raf kinases. Baljuls A, Kholodenko BN, Kolch W. Mol Biosyst 9 551-558 (2013)
  119. Targeted molecular therapy in melanoma. Puzanov I, Flaherty KT. Semin Cutan Med Surg 29 196-201 (2010)
  120. Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Swaika A, Crozier JA, Joseph RW. Drug Des Devel Ther 8 775-787 (2014)
  121. Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy. Gallagher SJ, Tiffen JC, Hersey P. Cancers (Basel) 7 1959-1982 (2015)
  122. The role of phenotypic plasticity in the escape of cancer cells from targeted therapy. Emmons MF, Faião-Flores F, Smalley KSM. Biochem Pharmacol 122 1-9 (2016)
  123. BRAF inhibitors: From the laboratory to clinical trials. Rahman MA, Salajegheh A, Smith RA, Lam AK. Crit Rev Oncol Hematol 90 220-232 (2014)
  124. Biological challenges of BRAF inhibitor therapy. Puzanov I, Burnett P, Flaherty KT. Mol Oncol 5 116-123 (2011)
  125. Cutaneous melanoma: a model to study cancer metastasis. Leong SP, Gershenwald JE, Soong SJ, Schadendorf D, Tarhini AA, Agarwala S, Hauschild A, Soon CW, Daud A, Kashani-Sabet M. J Surg Oncol 103 538-549 (2011)
  126. Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience. Khunger A, Khunger M, Velcheti V. Ther Adv Respir Dis 12 1753466618767611 (2018)
  127. Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics. Kim DH, Sim T. Arch Pharm Res 35 605-615 (2012)
  128. Inhibitors of phosphatidylinositol-3-kinase in cancer therapy. Ihle NT, Powis G. Mol Aspects Med 31 135-144 (2010)
  129. Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells. Kong Y, Kumar SM, Xu X. Arch Pathol Lab Med 134 1740-1749 (2010)
  130. Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come. Toschi L, Rossi S, Finocchiaro G, Santoro A. Ecancermedicalscience 11 787 (2017)
  131. Productivity shortfalls in drug discovery: contributions from the preclinical sciences? Williams M. J Pharmacol Exp Ther 336 3-8 (2011)
  132. The new paradigm of systemic therapies for metastatic melanoma. Volpe VO, Klufas DM, Hegde U, Grant-Kels JM. J Am Acad Dermatol 77 356-368 (2017)
  133. The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer. Bahrami A, Hesari A, Khazaei M, Hassanian SM, Ferns GA, Avan A. J Cell Physiol 233 2162-2169 (2018)
  134. Using genetics and genomics strategies to personalize therapy for cancer: focus on melanoma. Nathanson KL. Biochem Pharmacol 80 755-761 (2010)
  135. What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment. Bronte E, Bronte G, Novo G, Bronte F, Bavetta MG, Lo Re G, Lo Re G, Brancatelli G, Bazan V, Natoli C, Novo S, Russo A. Oncotarget 6 35589-35601 (2015)
  136. Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview. Fischer PM. Med Res Rev 37 314-367 (2017)
  137. Emerging Raf inhibitors. McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M. Expert Opin Emerg Drugs 14 633-648 (2009)
  138. Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF. Antonello ZA, Nucera C. Oncogene 33 5397-5404 (2014)
  139. PLX4032: does it keep its promise for metastatic melanoma treatment? Livingstone E, Zimmer L, Piel S, Schadendorf D. Expert Opin Investig Drugs 19 1439-1449 (2010)
  140. Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor). Torres-Collado AX, Knott J, Jazirehi AR. Cancers (Basel) 10 (2018)
  141. BRAF inhibitors and melanoma. Flaherty KT. Cancer J 17 505-511 (2011)
  142. Molecular mechanisms of asymmetric RAF dimer activation. Jambrina PG, Bohuszewicz O, Buchete NV, Kolch W, Rosta E. Biochem Soc Trans 42 784-790 (2014)
  143. Somatic alterations as the basis for resistance to targeted therapies. Blair BG, Bardelli A, Park BH. J Pathol 232 244-254 (2014)
  144. Systemic therapies for inflammatory eye disease: past, present and future. Denniston AK, Dick AD. BMC Ophthalmol 13 18 (2013)
  145. BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. Nakayama I, Hirota T, Shinozaki E. Cancers (Basel) 12 E3236 (2020)
  146. Current and future trials of targeted therapies in cutaneous melanoma. Evans MS, Madhunapantula SV, Robertson GP, Drabick JJ. Adv Exp Med Biol 779 223-255 (2013)
  147. Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy. Sun J, Zager JS, Eroglu Z. Onco Targets Ther 11 9081-9089 (2018)
  148. Major therapeutic developments and current challenges in advanced melanoma. Sullivan RJ, Flaherty KT. Br J Dermatol 170 36-44 (2014)
  149. Melanoma mutagenesis and aberrant cell signaling. Bello DM, Ariyan CE, Carvajal RD. Cancer Control 20 261-281 (2013)
  150. Molecular therapeutic approaches to melanoma. Ji Z, Flaherty KT, Tsao H. Mol Aspects Med 31 194-204 (2010)
  151. Targeted therapy for melanoma: a primer. Davies MA, Gershenwald JE. Surg Oncol Clin N Am 20 165-180 (2011)
  152. The ways and means of fragment-based drug design. Doak BC, Norton RS, Scanlon MJ. Pharmacol Ther 167 28-37 (2016)
  153. Transcriptional regulation in melanoma. Mitra D, Fisher DE. Hematol Oncol Clin North Am 23 447-65, viii (2009)
  154. Vemurafenib for the treatment of melanoma. Jordan EJ, Kelly CM. Expert Opin Pharmacother 13 2533-2543 (2012)
  155. BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma. Richman J, Martin-Liberal J, Diem S, Larkin J. Expert Opin Pharmacother 16 1285-1297 (2015)
  156. Clinical Pharmacokinetics of Vemurafenib. Zhang W, Heinzmann D, Grippo JF. Clin Pharmacokinet 56 1033-1043 (2017)
  157. DNA repair and cell cycle checkpoint defects as drivers and therapeutic targets in melanoma. Pavey S, Spoerri L, Haass NK, Gabrielli B. Pigment Cell Melanoma Res 26 805-816 (2013)
  158. Targeted therapy in melanoma. Kudchadkar RR, Smalley KS, Glass LF, Trimble JS, Sondak VK. Clin Dermatol 31 200-208 (2013)
  159. Current advances and perspectives in the treatment of advanced melanoma. Livingstone E, Zimmer L, Vaubel J, Schadendorf D. J Dtsch Dermatol Ges 10 319-325 (2012)
  160. Developments in targeted therapy in melanoma. Amann VC, Ramelyte E, Thurneysen S, Pitocco R, Bentele-Jaberg N, Goldinger SM, Dummer R, Mangana J. Eur J Surg Oncol 43 581-593 (2017)
  161. ER stress-induced autophagy in melanoma. Meng XX, Yao M, Zhang XD, Xu HX, Dong Q. Clin Exp Pharmacol Physiol 42 811-816 (2015)
  162. Stereotactic radiosurgery and immunotherapy for metastatic spinal melanoma. Caruso JP, Cohen-Inbar O, Bilsky MH, Gerszten PC, Sheehan JP. Neurosurg Focus 38 E6 (2015)
  163. Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71. Parenti R, Salvatorelli L, Magro G. Int J Endocrinol 2014 685396 (2014)
  164. Kinetic target-guided synthesis in drug discovery and chemical biology: a comprehensive facts and figures survey. Bosc D, Jakhlal J, Deprez B, Deprez-Poulain R. Future Med Chem 8 381-404 (2016)
  165. Overcoming Cancer Drug Resistance Utilizing PROTAC Technology. Burke MR, Smith AR, Zheng G. Front Cell Dev Biol 10 872729 (2022)
  166. Protein crystallography and fragment-based drug design. Caliandro R, Belviso DB, Aresta BM, de Candia M, Altomare CD. Future Med Chem 5 1121-1140 (2013)
  167. Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma. Pérez-Lorenzo R, Zheng B. Biosci Rep 32 25-33 (2012)
  168. The multifaceted anti-cancer effects of BRAF-inhibitors. Croce L, Croce L, Coperchini F, Magri F, Chiovato L, Rotondi M. Oncotarget 10 6623-6640 (2019)
  169. Therapeutic approaches to preventing cell death in Huntington disease. Kaplan A, Stockwell BR. Prog Neurobiol 99 262-280 (2012)
  170. Functional interrogation of kinases and other nucleotide-binding proteins. Rosenblum JS, Nomanbhoy TK, Kozarich JW. FEBS Lett 587 1870-1877 (2013)
  171. Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways. Lackner MR. Expert Rev Mol Diagn 10 75-87 (2010)
  172. Regulatory properties of statins and rho gtpases prenylation inhibitiors to stimulate melanoma immunogenicity and promote anti-melanoma immune response. Sarrabayrouse G, Pich C, Teiti I, Tilkin-Mariame AF. Int J Cancer 140 747-755 (2017)
  173. Vemurafenib for the treatment of BRAF mutant metastatic melanoma. Martin-Liberal J, Larkin J. Future Oncol 11 579-589 (2015)
  174. BRAF Alteration in Central and Peripheral Nervous System Tumors. Srinivasa K, Cross KA, Dahiya S. Front Oncol 10 574974 (2020)
  175. Combination Therapies for Melanoma: A New Standard of Care? Smalley KS, Eroglu Z, Sondak VK. Am J Clin Dermatol 17 99-105 (2016)
  176. Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy. Smalley KS, Fedorenko IV, Kenchappa RS, Sahebjam S, Forsyth PA. Int J Cancer 139 1195-1201 (2016)
  177. New RAF kinase inhibitors in cancer therapy. Martin-Liberal J, Larkin J. Expert Opin Pharmacother 15 1235-1245 (2014)
  178. Pre-clinical modeling of cutaneous melanoma. Rebecca VW, Somasundaram R, Herlyn M. Nat Commun 11 2858 (2020)
  179. Dabrafenib for treatment of BRAF-mutant melanoma. Kainthla R, Kim KB, Falchook GS. Pharmgenomics Pers Med 7 21-29 (2014)
  180. Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency. Khaliq M, Fallahi-Sichani M. Cancers (Basel) 11 (2019)
  181. Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond. Sullivan RJ, Atkins MB. Expert Opin Investig Drugs 19 1205-1216 (2010)
  182. Molecular-targeted therapy in malignant melanoma. Sullivan RJ, Atkins MB. Expert Rev Anticancer Ther 9 567-581 (2009)
  183. NMR-Fragment Based Virtual Screening: A Brief Overview. Singh M, Tam B, Akabayov B. Molecules 23 (2018)
  184. Novel therapies in melanoma. Scheier B, Amaria R, Lewis K, Gonzalez R. Immunotherapy 3 1461-1469 (2011)
  185. Patient-derived tumor xenograft models for melanoma drug discovery. Harris AL, Joseph RW, Copland JA. Expert Opin Drug Discov 11 895-906 (2016)
  186. Process of Fragment-Based Lead Discovery-A Perspective from NMR. Ma R, Wang P, Wu J, Ruan K. Molecules 21 (2016)
  187. Progress in melanoma modelling in vitro. Marconi A, Quadri M, Saltari A, Pincelli C. Exp Dermatol 27 578-586 (2018)
  188. Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements. Mizuarai S, Kotani H. Hum Genet 128 567-575 (2010)
  189. Targeting tyrosine kinases in cancer: the converging roles of cytopathology and molecular pathology in the era of genomic medicine. Dumur CI, Idowu MO, Powers CN. Cancer Cytopathol 121 61-71 (2013)
  190. Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations. Bradish JR, Montironi R, Lopez-Beltran A, Post KM, MacLennan GT, Cheng L. Future Oncol 9 245-253 (2013)
  191. Application of Fragment-Based Drug Discovery to Versatile Targets. Li Q. Front Mol Biosci 7 180 (2020)
  192. BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions. Proietti I, Skroza N, Michelini S, Mambrin A, Balduzzi V, Bernardini N, Marchesiello A, Tolino E, Volpe S, Maddalena P, Di Fraia M, Mangino G, Romeo G, Potenza C. Cancers (Basel) 12 (2020)
  193. Creating and screening natural product libraries. Wilson BAP, Thornburg CC, Henrich CJ, Grkovic T, O'Keefe BR. Nat Prod Rep 37 893-918 (2020)
  194. Developing melanoma therapeutics: overview and update. Korman JB, Fisher DE. Wiley Interdiscip Rev Syst Biol Med 5 257-271 (2013)
  195. Fragment-based drug discovery as alternative strategy to the drug development for neglected diseases. Mello JDFRE, Gomes RA, Vital-Fujii DG, Ferreira GM, Trossini GHG. Chem Biol Drug Des 90 1067-1078 (2017)
  196. In depth analysis of kinase cross screening data to identify chemical starting points for inhibition of the Nek family of kinases. Wells CI, Kapadia NR, Couñago RM, Drewry DH. Medchemcomm 9 44-66 (2018)
  197. Metastatic melanoma moves on: translational science in the era of personalized medicine. Levesque MP, Cheng PF, Raaijmakers MI, Saltari A, Dummer R. Cancer Metastasis Rev 36 7-21 (2017)
  198. Mitochondrial Dysfunction and Disturbed Coherence: Gate to Cancer. Pokorný J, Pokorný J, Foletti A, Kobilková J, Vrba J, Vrba J. Pharmaceuticals (Basel) 8 675-695 (2015)
  199. Novel approaches to inhibitor design for the p110β phosphoinositide 3-kinase. Dbouk HA, Backer JM. Trends Pharmacol Sci 34 149-153 (2013)
  200. Overcoming Immune Evasion in Melanoma. Eddy K, Chen S. Int J Mol Sci 21 (2020)
  201. Overcoming metastatic melanoma with BRAF inhibitors. Hong S, Hong S, Han SB. Arch Pharm Res 34 699-701 (2011)
  202. RAF signaling in neuroendocrine neoplasms: from bench to bedside. Fazio N, Abdel-Rahman O, Spada F, Galdy S, De Dosso S, Capdevila J, Scarpa A. Cancer Treat Rev 40 974-979 (2014)
  203. Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy. Barutello G, Rolih V, Arigoni M, Tarone L, Conti L, Quaglino E, Buracco P, Cavallo F, Riccardo F. Int J Mol Sci 19 (2018)
  204. Structural simplification: an efficient strategy in lead optimization. Wang S, Dong G, Sheng C. Acta Pharm Sin B 9 880-901 (2019)
  205. The GIST of targeted therapy for malignant melanoma. Bello DM, Dematteo RP, Ariyan CE. Ann Surg Oncol 21 2059-2067 (2014)
  206. Vemurafenib in melanoma. Shaw HM, Nathan PD. Expert Rev Anticancer Ther 13 513-522 (2013)
  207. Vemurafenib: in unresectable or metastatic melanoma. Keating GM. BioDrugs 26 325-334 (2012)
  208. A decade of the human genome sequence--how does the medicinal chemist benefit? Brunschweiger A, Hall J. ChemMedChem 7 194-203 (2012)
  209. Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond. Zhou AY, Johnson DB. Am J Clin Dermatol 19 181-193 (2018)
  210. Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer. Pan JH, Zhou H, Zhu SB, Huang JL, Zhao XX, Ding H, Pan YL. Cancer Manag Res 10 2289-2301 (2018)
  211. Drug resistance in targeted cancer therapies with RAF inhibitors. Degirmenci U, Yap J, Sim YRM, Qin S, Hu J. Cancer Drug Resist 4 665-683 (2021)
  212. Immunotherapy in glioblastoma: emerging options in precision medicine. Hodges TR, Ferguson SD, Heimberger AB. CNS Oncol 5 175-186 (2016)
  213. Phase I/II RAF kinase inhibitors in cancer therapy. Turajlic S, Ali Z, Yousaf N, Larkin J. Expert Opin Investig Drugs 22 739-749 (2013)
  214. Scaffold-based design of kinase inhibitors for cancer therapy. Zhang C, Bollag G. Curr Opin Genet Dev 20 79-86 (2010)
  215. The pharmacogenomics of drug resistance to protein kinase inhibitors. Gillis NK, McLeod HL. Drug Resist Updat 28 28-42 (2016)
  216. Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors. Adashek JJ, Menta AK, Reddy NK, Desai AP, Roszik J, Subbiah V. Mol Cancer Ther 21 871-878 (2022)
  217. Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma. Saei A, Eichhorn PJA. Cancers (Basel) 11 (2019)
  218. Biased and unbiased strategies to identify biologically active small molecules. Abet V, Mariani A, Truscott FR, Britton S, Rodriguez R. Bioorg Med Chem 22 4474-4489 (2014)
  219. Molecularly targeted therapies for melanoma. Liu LS, Colegio OR, Colegio OR. Int J Dermatol 52 523-530 (2013)
  220. Protein X-ray Crystallography and Drug Discovery. Maveyraud L, Mourey L. Molecules 25 (2020)
  221. Radiotherapy with BRAF inhibitor therapy for melanoma: progress and possibilities. Zahnreich S, Mayer A, Loquai C, Grabbe S, Schmidberger H. Future Oncol 12 95-106 (2016)
  222. Change or die: targeting adaptive signaling to kinase inhibition in cancer cells. Rebecca VW, Smalley KS. Biochem Pharmacol 91 417-425 (2014)
  223. Crosstalk of the Wnt/β-Catenin Signaling Pathway in the Induction of Apoptosis on Cancer Cells. Trejo-Solis C, Escamilla-Ramirez A, Jimenez-Farfan D, Castillo-Rodriguez RA, Flores-Najera A, Cruz-Salgado A. Pharmaceuticals (Basel) 14 871 (2021)
  224. A new approach to assess drug sensitivity in cells for novel drug discovery. Mazzarella L, Curigliano G. Expert Opin Drug Discov 13 339-346 (2018)
  225. Clinical trials in drug development: a minimalistic approach. Verweij J. Curr Opin Oncol 24 332-337 (2012)
  226. KRAS as a Key Oncogene in the Clinical Precision Diagnosis and Treatment of Pancreatic Cancer. Dai M, Chen S, Teng X, Chen K, Cheng W. J Cancer 13 3209-3220 (2022)
  227. Protein kinases: From targets to anti-cancer drugs. Cruzalegui F. Ann Pharm Fr 68 254-259 (2010)
  228. Small-Molecule Screening for Genetic Diseases. Markossian S, Ang KK, Wilson CG, Arkin MR. Annu Rev Genomics Hum Genet 19 263-288 (2018)
  229. Translational pathology, genomics and the development of systemic therapies for acral melanoma. Chen YA, Teer JK, Eroglu Z, Wu JY, Koomen JM, Karreth FA, Messina JL, Smalley KSM. Semin Cancer Biol 61 149-157 (2020)
  230. Approaches toward improving the prognosis of pediatric patients with glioma: pursuing mutant drug targets with emerging small molecules. Snape TJ, Warr T. Semin Pediatr Neurol 22 28-34 (2015)
  231. Bench to bedside: mechanistic principles of targeting the RAF kinase in melanoma. Rajakulendran T, Adam DN. Int J Dermatol 53 1428-1433 (2014)
  232. Drug safety evaluation of vemurafenib in the treatment of melanoma. Tsai KY, Nowroozi S, Kim KB. Expert Opin Drug Saf 12 767-775 (2013)
  233. Inflammation and aging: signaling pathways and intervention therapies. Li X, Li C, Zhang W, Wang Y, Qian P, Huang H. Signal Transduct Target Ther 8 239 (2023)
  234. Pyrazolo[3,4-b]pyridine kinase inhibitors: a patent review (2008--present). Wenglowsky S. Expert Opin Ther Pat 23 281-298 (2013)
  235. Recent advances in non-small cell lung cancer targeted therapy; an update review. Araghi M, Mannani R, Heidarnejad Maleki A, Hamidi A, Rostami S, Safa SH, Faramarzi F, Khorasani S, Alimohammadi M, Tahmasebi S, Akhavan-Sigari R. Cancer Cell Int 23 162 (2023)
  236. Targeting pan-essential genes in cancer: Challenges and opportunities. Chang L, Ruiz P, Ito T, Sellers WR. Cancer Cell 39 466-479 (2021)
  237. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. Bahar ME, Kim HJ, Kim DR. Signal Transduct Target Ther 8 455 (2023)
  238. [Mutation of the BRAF genes in non-small cell lung cancer]. Huang Z, Wu Y. Zhongguo Fei Ai Za Zhi 15 183-186 (2012)
  239. 19F NMR viewed through two different lenses: ligand-observed and protein-observed 19F NMR applications for fragment-based drug discovery. Buchholz CR, Pomerantz WCK. RSC Chem Biol 2 1312-1330 (2021)
  240. Advances in high-throughput mass spectrometry in drug discovery. Dueñas ME, Peltier-Heap RE, Leveridge M, Annan RS, Büttner FH, Trost M. EMBO Mol Med 15 e14850 (2023)
  241. Beyond RAS and BRAF: a target rich disease that is ripe for picking. Friedrich T, Leong S, Lieu CH. J Gastrointest Oncol 7 705-712 (2016)
  242. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma. Kim HY, Upadhyay PJ, Fahmy A, Liu X, Duong JK, Boddy AV. Clin Pharmacokinet 58 1029-1043 (2019)
  243. Discovering new biology with drug-resistance alleles. Freedy AM, Liau BB. Nat Chem Biol 17 1219-1229 (2021)
  244. Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in BRAF and p.R461* in NF1 Genes-A Case Report with Literature Review. Grenda A, Krawczyk P, Targowska-Duda KM, Kieszko R, Paśnik I, Milanowski J. Int J Mol Sci 24 1195 (2023)
  245. Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell Therapy. Jazirehi AR. Int J Mol Sci 22 11726 (2021)
  246. Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells. Hamid AB, Petreaca RC. Cancers (Basel) 12 (2020)
  247. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang W, Tian C, Miao Z, Wang T, Yang S. Signal Transduct Target Ther 6 201 (2021)
  248. Tailoring the Treatment of Melanoma: Implications for Personalized Medicine. Duan L, Mukherjee EM, Narayan D. Yale J Biol Med 88 389-395 (2015)
  249. Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy. Li Q, Li Z, Luo T, Shi H. Mol Biomed 3 47 (2022)
  250. The Nuclear Pore Complex and mRNA Export in Cancer. Borden KLB. Cancers (Basel) 13 (2020)
  251. [Advances on driver oncogenes of lung adenocarcinoma]. Wang J, Zhang Z, Zhang S. Zhongguo Fei Ai Za Zhi 16 91-96 (2013)
  252. [Fragment-based screening: a promising avenue for drug design]. Krimm I. Med Sci (Paris) 31 197-202 (2015)
  253. Approved Small-Molecule ATP-Competitive Kinases Drugs Containing Indole/Azaindole/Oxindole Scaffolds: R&D and Binding Patterns Profiling. Zhang H, He F, Gao G, Lu S, Wei Q, Hu H, Wu Z, Fang M, Wang X. Molecules 28 943 (2023)
  254. Changing pathology with changing drugs: skin cancer. Karpova MB, Barysch MJ, Zipser MC, Schönewolf N, French LE, Dummer R. Pathobiology 78 61-75 (2011)
  255. Evaluating the consistency of large-scale pharmacogenomic studies. Rahman R, Dhruba SR, Matlock K, De-Niz C, Ghosh S, Pal R. Brief Bioinform 20 1734-1753 (2019)
  256. Immune Checkpoint Inhibitors and RAS-ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma. Morante M, Pandiella A, Crespo P, Herrero A. Biomolecules 12 1562 (2022)
  257. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma. Lelliott EJ, McArthur GA, Oliaro J, Sheppard KE. Front Immunol 12 661737 (2021)
  258. Increased Cell Proliferation as a Key Event in Chemical Carcinogenesis: Application in an Integrated Approach for the Testing and Assessment of Non-Genotoxic Carcinogenesis. Strupp C, Corvaro M, Cohen SM, Corton JC, Ogawa K, Richert L, Jacobs MN. Int J Mol Sci 24 13246 (2023)
  259. Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma. Dobre EG, Constantin C, Costache M, Neagu M. J Pers Med 11 (2021)
  260. Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanoma. Eliades P, Flaherty KT, Tsao H. Melanoma Manag 2 133-147 (2015)
  261. Recent advances in targeting protein kinases and pseudokinases in cancer biology. Riegel K, Vijayarangakannan P, Kechagioglou P, Bogucka K, Rajalingam K. Front Cell Dev Biol 10 942500 (2022)
  262. Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis. Wang L, Liu WQ, Broussy S, Han B, Fang H. Front Pharmacol 14 1307860 (2023)
  263. Response and resistance to BRAFV600E inhibition in gliomas: Roadblocks ahead? Capogiri M, De Micheli AJ, Lassaletta A, Muñoz DP, Coppé JP, Mueller S, Guerreiro Stucklin AS. Front Oncol 12 1074726 (2022)
  264. Selected Approaches to Disrupting Protein-Protein Interactions within the MAPK/RAS Pathway. Harwood SJ, Smith CR, Lawson JD, Ketcham JM. Int J Mol Sci 24 7373 (2023)
  265. Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials. Song Y, Bi Z, Liu Y, Qin F, Wei Y, Wei X. Genes Dis 10 76-88 (2023)
  266. Targeting protein tyrosine kinase 6 in cancer. Gilic MB, Tyner AL. Biochim Biophys Acta Rev Cancer 1874 188432 (2020)

Articles citing this publication (482)

  1. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group. N Engl J Med 364 2507-2516 (2011)
  2. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jané-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P, de Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, Garraway LA. Nature 483 603-607 (2012)
  3. Inhibition of mutated, activated BRAF in metastatic melanoma. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. N Engl J Med 363 809-819 (2010)
  4. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS. Nature 468 973-977 (2010)
  5. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. N Engl J Med 366 707-714 (2012)
  6. Improved survival with MEK inhibition in BRAF-mutated melanoma. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D, METRIC Study Group. N Engl J Med 367 107-114 (2012)
  7. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. Nature 464 427-430 (2010)
  8. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA. Nature 468 968-972 (2010)
  9. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S. Nature 464 431-435 (2010)
  10. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R. Cell 140 209-221 (2010)
  11. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL, Coussens LM. Cancer Discov 1 54-67 (2011)
  12. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M. Cancer Cell 18 683-695 (2010)
  13. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE, You MJ, DePinho RA, McMahon M, Bosenberg M. Nat Genet 41 544-552 (2009)
  14. Drug target identification using side-effect similarity. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Science 321 263-266 (2008)
  15. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R. N Engl J Med 366 207-215 (2012)
  16. BRAF mutations in hairy-cell leukemia. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, Foà R, Farinelli L, Haferlach T, Pasqualucci L, Rabadan R, Falini B. N Engl J Med 364 2305-2315 (2011)
  17. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG. Cancer Res 74 5057-5069 (2014)
  18. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck MJ, Gray NS, Jänne PA. Nature 462 1070-1074 (2009)
  19. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D, Hewitt S, Udupi GM, Gallagher WM, Wegner C, West BL, Wang-Gillam A, Goedegebuure P, Linehan DC, DeNardo DG. Cancer Res 73 1128-1141 (2013)
  20. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, Sacks JD, Raimondi A, Majer CR, Song J, Scott MP, Jin L, Smith JJ, Olhava EJ, Chesworth R, Moyer MP, Richon VM, Copeland RA, Keilhack H, Pollock RM, Kuntz KW. Nat Chem Biol 8 890-896 (2012)
  21. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, MacConaill LE, Zhang J, Gray NS, Sellers WR, Dummer R, Garraway LA. Proc Natl Acad Sci U S A 106 20411-20416 (2009)
  22. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A, Tsai J, Chapman PB, Bollag G, Solit DB, Rosen N. Proc Natl Acad Sci U S A 107 14903-14908 (2010)
  23. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong WL, Callahan MK, Merghoub T, Wolchok JD, de Stanchina E, Chandarlapaty S, Poulikakos PI, Fagin JA, Rosen N. Cancer Cell 22 668-682 (2012)
  24. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Kaplon J, Zheng L, Meissl K, Chaneton B, Selivanov VA, Mackay G, van der Burg SH, Verdegaal EM, Cascante M, Shlomi T, Gottlieb E, Peeper DS. Nature 498 109-112 (2013)
  25. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Müller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Geukes Foppen MH, Kemper K, Goding CR, McDermott U, Blank C, Haanen J, Graeber TG, Ribas A, Lo RS, Peeper DS. Nat Commun 5 5712 (2014)
  26. A dimerization-dependent mechanism drives RAF catalytic activation. Rajakulendran T, Sahmi M, Lefrançois M, Sicheri F, Therrien M. Nature 461 542-545 (2009)
  27. DHODH modulates transcriptional elongation in the neural crest and melanoma. White RM, Cech J, Ratanasirintrawoot S, Lin CY, Rahl PB, Burke CJ, Langdon E, Tomlinson ML, Mosher J, Kaufman C, Chen F, Long HK, Kramer M, Datta S, Neuberg D, Granter S, Young RA, Morrison S, Wheeler GN, Zon LI. Nature 471 518-522 (2011)
  28. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, Krauthammer M, McCusker JP, Kluger Y, Sznol M. Pigment Cell Melanoma Res 23 190-200 (2010)
  29. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, Zambon A, Sinclair J, Hayes A, Gore M, Lorigan P, Springer C, Larkin J, Jorgensen C, Marais R. Cancer Discov 3 158-167 (2013)
  30. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Tompers Frederick D, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, Woodman SE, Davies MA, Radvanyi LG, Overwijk WW, Lizée G, Hwu P. Clin Cancer Res 19 393-403 (2013)
  31. Raf family kinases: old dogs have learned new tricks. Matallanas D, Birtwistle M, Romano D, Zebisch A, Rauch J, von Kriegsheim A, Kolch W. Genes Cancer 2 232-260 (2011)
  32. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, Bollag G, Kolesnick R, Thin TH, Rosen N, Zanzonico P, Larson SM, Refetoff S, Ghossein R, Fagin JA. J Clin Invest 121 4700-4711 (2011)
  33. In situ kinase profiling reveals functionally relevant properties of native kinases. Patricelli MP, Nomanbhoy TK, Wu J, Brown H, Zhou D, Zhang J, Jagannathan S, Aban A, Okerberg E, Herring C, Nordin B, Weissig H, Yang Q, Lee JD, Gray NS, Kozarich JW. Chem Biol 18 699-710 (2011)
  34. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Blasco RB, Francoz S, Santamaría D, Cañamero M, Dubus P, Charron J, Baccarini M, Barbacid M. Cancer Cell 19 652-663 (2011)
  35. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S. Clin Cancer Res 19 657-667 (2013)
  36. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C, Yeap BY, Sholl LM, Johnson BE, Jänne PA. Clin Cancer Res 19 4532-4540 (2013)
  37. RAF inhibitors that evade paradoxical MAPK pathway activation. Zhang C, Spevak W, Zhang Y, Burton EA, Ma Y, Habets G, Zhang J, Lin J, Ewing T, Matusow B, Tsang G, Marimuthu A, Cho H, Wu G, Wang W, Fong D, Nguyen H, Shi S, Womack P, Nespi M, Shellooe R, Carias H, Powell B, Light E, Sanftner L, Walters J, Tsai J, West BL, Visor G, Rezaei H, Lin PS, Nolop K, Ibrahim PN, Hirth P, Bollag G. Nature 526 583-586 (2015)
  38. Allosteric activation of functionally asymmetric RAF kinase dimers. Hu J, Stites EC, Yu H, Yu H, Germino EA, Meharena HS, Stork PJS, Kornev AP, Taylor SS, Shaw AS. Cell 154 1036-1046 (2013)
  39. Assessing the performance of MM/PBSA and MM/GBSA methods. 5. Improved docking performance using high solute dielectric constant MM/GBSA and MM/PBSA rescoring. Sun H, Li Y, Shen M, Tian S, Xu L, Pan P, Guan Y, Hou T. Phys Chem Chem Phys 16 22035-22045 (2014)
  40. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. Søndergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar H, MacConaill LE, Barretina JG, Kehoe SM, Attar N, von Euw E, Zuckerman JE, Chmielowski B, Comin-Anduix B, Koya RC, Mischel PS, Lo RS, Ribas A. J Transl Med 8 39 (2010)
  41. Progression of RAS-mutant leukemia during RAF inhibitor treatment. Callahan MK, Rampal R, Harding JJ, Klimek VM, Chung YR, Merghoub T, Wolchok JD, Solit DB, Rosen N, Abdel-Wahab O, Levine RL, Chapman PB. N Engl J Med 367 2316-2321 (2012)
  42. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Shao Y, Aplin AE. Cancer Res 70 6670-6681 (2010)
  43. The evolving war on cancer. Haber DA, Gray NS, Baselga J. Cell 145 19-24 (2011)
  44. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E, Finn S, Jarzab B, Hodin RA, Pontecorvi A, Nose V, Lawler J, Parangi S. Proc Natl Acad Sci U S A 107 10649-10654 (2010)
  45. A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling. Athuluri-Divakar SK, Vasquez-Del Carpio R, Dutta K, Baker SJ, Cosenza SC, Basu I, Gupta YK, Reddy MV, Ueno L, Hart JR, Vogt PK, Mulholland D, Guha C, Aggarwal AK, Reddy EP. Cell 165 643-655 (2016)
  46. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. Peng SB, Henry JR, Kaufman MD, Lu WP, Smith BD, Vogeti S, Rutkoski TJ, Wise S, Chun L, Zhang Y, Van Horn RD, Yin T, Zhang X, Yadav V, Chen SH, Gong X, Ma X, Webster Y, Buchanan S, Mochalkin I, Huber L, Kays L, Donoho GP, Walgren J, McCann D, Patel P, Conti I, Plowman GD, Starling JJ, Flynn DL. Cancer Cell 28 384-398 (2015)
  47. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, Iafrate AJ, Sosman J, Pao W. PLoS One 7 e35309 (2012)
  48. The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury. Li JX, Feng JM, Wang Y, Li XH, Chen XX, Su Y, Shen YY, Chen Y, Xiong B, Yang CH, Ding J, Miao ZH. Cell Death Dis 5 e1278 (2014)
  49. BRAF mutation status in gastrointestinal stromal tumors. Hostein I, Faur N, Primois C, Boury F, Denard J, Emile JF, Bringuier PP, Scoazec JY, Coindre JM. Am J Clin Pathol 133 141-148 (2010)
  50. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Xing F, Persaud Y, Pratilas CA, Taylor BS, Janakiraman M, She QB, Gallardo H, Liu C, Merghoub T, Hefter B, Dolgalev I, Viale A, Heguy A, De Stanchina E, Cobrinik D, Bollag G, Wolchok J, Houghton A, Solit DB. Oncogene 31 446-457 (2012)
  51. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. Yadav V, Zhang X, Liu J, Estrem S, Li S, Gong XQ, Buchanan S, Henry JR, Starling JJ, Peng SB. J Biol Chem 287 28087-28098 (2012)
  52. Targeted therapy for BRAFV600E malignant astrocytoma. Nicolaides TP, Li H, Solomon DA, Hariono S, Hashizume R, Barkovich K, Baker SJ, Paugh BS, Jones C, Forshew T, Hindley GF, Hodgson JG, Kim JS, Rowitch DH, Weiss WA, Waldman TA, James CD. Clin Cancer Res 17 7595-7604 (2011)
  53. The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. Fenouille N, Tichet M, Dufies M, Pottier A, Mogha A, Soo JK, Rocchi S, Mallavialle A, Galibert MD, Khammari A, Lacour JP, Ballotti R, Deckert M, Tartare-Deckert S. PLoS One 7 e40378 (2012)
  54. PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Lee JT, Li L, Brafford PA, van den Eijnden M, Halloran MB, Sproesser K, Haass NK, Smalley KS, Tsai J, Bollag G, Herlyn M. Pigment Cell Melanoma Res 23 820-827 (2010)
  55. A ring-distortion strategy to construct stereochemically complex and structurally diverse compounds from natural products. Huigens RW, Morrison KC, Hicklin RW, Flood TA, Richter MF, Hergenrother PJ. Nat Chem 5 195-202 (2013)
  56. Structural basis of RIP1 inhibition by necrostatins. Xie T, Peng W, Liu Y, Yan C, Maki J, Degterev A, Yuan J, Shi Y. Structure 21 493-499 (2013)
  57. Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Biechele TL, Kulikauskas RM, Toroni RA, Lucero OM, Swift RD, James RG, Robin NC, Dawson DW, Moon RT, Chien AJ. Sci Signal 5 ra3 (2012)
  58. Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene. Hall A, Meyle KD, Lange MK, Klima M, Sanderhoff M, Dahl C, Abildgaard C, Thorup K, Moghimi SM, Jensen PB, Bartek J, Guldberg P, Christensen C. Oncotarget 4 584-599 (2013)
  59. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF. J Pharmacol Exp Ther 342 33-40 (2012)
  60. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. Anastas JN, Kulikauskas RM, Tamir T, Rizos H, Long GV, von Euw EM, Yang PT, Chen HW, Haydu L, Toroni RA, Lucero OM, Chien AJ, Moon RT. J Clin Invest 124 2877-2890 (2014)
  61. The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island Methylator phenotype. Fang M, Ou J, Hutchinson L, Green MR. Mol Cell 55 904-915 (2014)
  62. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF. Hu J, Yu H, Yu H, Kornev AP, Zhao J, Filbert EL, Taylor SS, Shaw AS. Proc Natl Acad Sci U S A 108 6067-6072 (2011)
  63. Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling. Haling JR, Sudhamsu J, Yen I, Sideris S, Sandoval W, Phung W, Bravo BJ, Giannetti AM, Peck A, Masselot A, Morales T, Smith D, Brandhuber BJ, Hymowitz SG, Malek S. Cancer Cell 26 402-413 (2014)
  64. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. King AJ, Arnone MR, Bleam MR, Moss KG, Yang J, Fedorowicz KE, Smitheman KN, Erhardt JA, Hughes-Earle A, Kane-Carson LS, Sinnamon RH, Qi H, Rheault TR, Uehling DE, Laquerre SG. PLoS One 8 e67583 (2013)
  65. Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling. Nan X, Collisson EA, Lewis S, Huang J, Tamgüney TM, Liphardt JT, McCormick F, Gray JW, Chu S. Proc Natl Acad Sci U S A 110 18519-18524 (2013)
  66. AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade. Smith FD, Langeberg LK, Cellurale C, Pawson T, Morrison DK, Davis RJ, Scott JD. Nat Cell Biol 12 1242-1249 (2010)
  67. Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. Röring M, Herr R, Fiala GJ, Heilmann K, Braun S, Eisenhardt AE, Halbach S, Capper D, von Deimling A, Schamel WW, Saunders DN, Brummer T. EMBO J 31 2629-2647 (2012)
  68. Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Whittaker S, Kirk R, Hayward R, Zambon A, Viros A, Cantarino N, Affolter A, Nourry A, Niculescu-Duvaz D, Springer C, Marais R. Sci Transl Med 2 35ra41 (2010)
  69. Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Sambade MJ, Peters EC, Thomas NE, Kaufmann WK, Kimple RJ, Shields JM. Radiother Oncol 98 394-399 (2011)
  70. BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model. Perna D, Karreth FA, Rust AG, Perez-Mancera PA, Rashid M, Iorio F, Alifrangis C, Arends MJ, Bosenberg MW, Bollag G, Tuveson DA, Adams DJ. Proc Natl Acad Sci U S A 112 E536-45 (2015)
  71. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Cartlidge RA, Thomas GR, Cagnol S, Jong KA, Molton SA, Finch AJ, McMahon M. Pigment Cell Melanoma Res 21 534-544 (2008)
  72. Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Lin J, Goto Y, Murata H, Sakaizawa K, Uchiyama A, Saida T, Takata M. Br J Cancer 104 464-468 (2011)
  73. Understanding melanoma signaling networks as the basis for molecular targeted therapy. Smalley KS. J Invest Dermatol 130 28-37 (2010)
  74. The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. Watson IR, Li L, Cabeceiras PK, Mahdavi M, Gutschner T, Genovese G, Wang G, Fang Z, Tepper JM, Stemke-Hale K, Tsai KY, Davies MA, Mills GB, Chin L. Cancer Res 74 4845-4852 (2014)
  75. News Vemurafenib. Flaherty KT, Yasothan U, Kirkpatrick P. Nat Rev Drug Discov 10 811-812 (2011)
  76. Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation. Thevakumaran N, Lavoie H, Critton DA, Tebben A, Marinier A, Sicheri F, Therrien M. Nat Struct Mol Biol 22 37-43 (2015)
  77. Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Jiang CC, Lai F, Tay KH, Croft A, Rizos H, Becker TM, Yang F, Liu H, Thorne RF, Hersey P, Zhang XD. Cell Death Dis 1 e69 (2010)
  78. Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. Christopher JA, Brown J, Doré AS, Errey JC, Koglin M, Marshall FH, Myszka DG, Rich RL, Tate CG, Tehan B, Warne T, Congreve M. J Med Chem 56 3446-3455 (2013)
  79. ERK/p90(RSK)/14-3-3 signalling has an impact on expression of PEA3 Ets transcription factors via the transcriptional repressor capicúa. Dissanayake K, Toth R, Blakey J, Olsson O, Campbell DG, Prescott AR, MacKintosh C. Biochem J 433 515-525 (2011)
  80. Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. Kaplan FM, Shao Y, Mayberry MM, Aplin AE. Oncogene 30 366-371 (2011)
  81. ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system. Polier S, Samant RS, Clarke PA, Workman P, Prodromou C, Pearl LH. Nat Chem Biol 9 307-312 (2013)
  82. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Holderfield M, Merritt H, Chan J, Wallroth M, Tandeske L, Zhai H, Tellew J, Hardy S, Hekmat-Nejad M, Stuart DD, McCormick F, Nagel TE. Cancer Cell 23 594-602 (2013)
  83. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Deng W, Gopal YN, Scott A, Chen G, Woodman SE, Davies MA. Pigment Cell Melanoma Res 25 248-258 (2012)
  84. Fibroblasts contribute to melanoma tumor growth and drug resistance. Flach EH, Rebecca VW, Herlyn M, Smalley KS, Anderson AR. Mol Pharm 8 2039-2049 (2011)
  85. Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. Anavi-Goffer S, Baillie G, Irving AJ, Gertsch J, Greig IR, Pertwee RG, Ross RA. J Biol Chem 287 91-104 (2012)
  86. Targeting Akt3 signaling in malignant melanoma using isoselenocyanates. Sharma A, Sharma AK, Madhunapantula SV, Desai D, Huh SJ, Mosca P, Amin S, Robertson GP. Clin Cancer Res 15 1674-1685 (2009)
  87. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Nucera C, Nehs MA, Nagarkatti SS, Sadow PM, Mekel M, Fischer AH, Lin PS, Bollag GE, Lawler J, Hodin RA, Parangi S. Oncologist 16 296-309 (2011)
  88. Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. Pichler M, Balic M, Stadelmeyer E, Ausch C, Wild M, Guelly C, Bauernhofer T, Samonigg H, Hoefler G, Dandachi N. J Mol Diagn 11 140-147 (2009)
  89. Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions. Klein RM, Aplin AE. Cancer Res 69 2224-2233 (2009)
  90. A phase II trial of sorafenib in metastatic melanoma with tissue correlates. Ott PA, Hamilton A, Min C, Safarzadeh-Amiri S, Goldberg L, Yoon J, Yee H, Buckley M, Christos PJ, Wright JJ, Polsky D, Osman I, Liebes L, Pavlick AC. PLoS One 5 e15588 (2010)
  91. Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors. Rheault TR, Stellwagen JC, Adjabeng GM, Hornberger KR, Petrov KG, Waterson AG, Dickerson SH, Mook RA, Laquerre SG, King AJ, Rossanese OW, Arnone MR, Smitheman KN, Kane-Carson LS, Han C, Moorthy GS, Moss KG, Uehling DE. ACS Med Chem Lett 4 358-362 (2013)
  92. RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling. McKay MM, Ritt DA, Morrison DK. Curr Biol 21 563-568 (2011)
  93. A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. Mass E, Jacome-Galarza CE, Blank T, Lazarov T, Durham BH, Ozkaya N, Pastore A, Schwabenland M, Chung YR, Rosenblum MK, Prinz M, Abdel-Wahab O, Geissmann F. Nature 549 389-393 (2017)
  94. Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis. Gril B, Palmieri D, Qian Y, Smart D, Ileva L, Liewehr DJ, Steinberg SM, Steeg PS. Clin Cancer Res 17 142-153 (2011)
  95. Necroptosis is a novel mechanism of radiation-induced cell death in anaplastic thyroid and adrenocortical cancers. Nehs MA, Lin CI, Kozono DE, Whang EE, Cho NL, Zhu K, Moalem J, Moore FD, Ruan DT. Surgery 150 1032-1039 (2011)
  96. Role and regulation of STAT3 phosphorylation at Ser727 in melanocytes and melanoma cells. Sakaguchi M, Oka M, Iwasaki T, Fukami Y, Nishigori C. J Invest Dermatol 132 1877-1885 (2012)
  97. Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma. Packer LM, East P, Reis-Filho JS, Marais R. Pigment Cell Melanoma Res 22 785-798 (2009)
  98. P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. Ong CC, Jubb AM, Jakubiak D, Zhou W, Rudolph J, Haverty PM, Kowanetz M, Yan Y, Tremayne J, Lisle R, Harris AL, Friedman LS, Belvin M, Middleton MR, Blackwood EM, Koeppen H, Hoeflich KP. J Natl Cancer Inst 105 606-607 (2013)
  99. Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress. Croft A, Tay KH, Boyd SC, Guo ST, Jiang CC, Lai F, Tseng HY, Jin L, Rizos H, Hersey P, Zhang XD. J Invest Dermatol 134 488-497 (2014)
  100. Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Artis DR, Lin JJ, Zhang C, Wang W, Mehra U, Perreault M, Erbe D, Krupka HI, England BP, Arnold J, Plotnikov AN, Marimuthu A, Nguyen H, Will S, Signaevsky M, Kral J, Cantwell J, Settachatgull C, Yan DS, Fong D, Oh A, Shi S, Womack P, Powell B, Habets G, West BL, Zhang KY, Milburn MV, Vlasuk GP, Hirth KP, Nolop K, Bollag G, Ibrahim PN, Tobin JF. Proc Natl Acad Sci U S A 106 262-267 (2009)
  101. Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. Frumm SM, Fan ZP, Ross KN, Duvall JR, Gupta S, VerPlank L, Suh BC, Holson E, Wagner FF, Smith WB, Paranal RM, Bassil CF, Qi J, Roti G, Kung AL, Bradner JE, Tolliday N, Stegmaier K. Chem Biol 20 713-725 (2013)
  102. Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells. Bourcier C, Griseri P, Grépin R, Bertolotto C, Mazure N, Pagès G. Am J Physiol Cell Physiol 301 C609-18 (2011)
  103. Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition. Metzner T, Bedeir A, Held G, Peter-Vörösmarty B, Ghassemi S, Heinzle C, Spiegl-Kreinecker S, Marian B, Holzmann K, Grasl-Kraupp B, Pirker C, Micksche M, Berger W, Heffeter P, Grusch M. J Invest Dermatol 131 2087-2095 (2011)
  104. Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies. Lee HJ, Wall BA, Wangari-Talbot J, Shin SS, Rosenberg S, Chan JL, Namkoong J, Goydos JS, Chen S. Clin Cancer Res 17 7080-7092 (2011)
  105. Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer--Evidence for a Relevant Model System and Urine-Based Diagnostic Test. Decker B, Parker HG, Dhawan D, Kwon EM, Karlins E, Davis BW, Ramos-Vara JA, Bonney PL, McNiel EA, Knapp DW, Ostrander EA. Mol Cancer Res 13 993-1002 (2015)
  106. Real-time cell cycle imaging during melanoma growth, invasion, and drug response. Haass NK, Beaumont KA, Hill DS, Anfosso A, Mrass P, Munoz MA, Kinjyo I, Weninger W. Pigment Cell Melanoma Res 27 764-776 (2014)
  107. BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma. Shao Y, Aplin AE. Cell Death Differ 19 2029-2039 (2012)
  108. BRAFV600 inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells. Lunavat TR, Cheng L, Einarsdottir BO, Olofsson Bagge R, Veppil Muralidharan S, Sharples RA, Lässer C, Gho YS, Hill AF, Nilsson JA, Lötvall J. Proc Natl Acad Sci U S A 114 E5930-E5939 (2017)
  109. High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Kiessling MK, Oberholzer PA, Mondal C, Karpova MB, Zipser MC, Lin WM, Girardi M, Macconaill LE, Kehoe SM, Hatton C, French LE, Garraway LA, Polier G, Süss D, Klemke CD, Krammer PH, Gülow K, Dummer R. Blood 117 2433-2440 (2011)
  110. BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling. Vin H, Ojeda SS, Ching G, Leung ML, Chitsazzadeh V, Dwyer DW, Adelmann CH, Restrepo M, Richards KN, Stewart LR, Du L, Ferguson SB, Chakravarti D, Ehrenreiter K, Baccarini M, Ruggieri R, Curry JL, Kim KB, Ciurea AM, Duvic M, Prieto VG, Ullrich SE, Dalby KN, Flores ER, Tsai KY. Elife 2 e00969 (2013)
  111. Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis. Erkes DA, Cai W, Sanchez IM, Purwin TJ, Rogers C, Field CO, Berger AC, Hartsough EJ, Rodeck U, Alnemri ES, Aplin AE. Cancer Discov 10 254-269 (2020)
  112. Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Basile KJ, Abel EV, Aplin AE. Oncogene 31 2471-2479 (2012)
  113. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance. Wroblewski D, Mijatov B, Mohana-Kumaran N, Lai F, Gallagher SJ, Haass NK, Zhang XD, Hersey P. Carcinogenesis 34 237-247 (2013)
  114. The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase. Xie P, Streu C, Qin J, Bregman H, Pagano N, Meggers E, Marmorstein R. Biochemistry 48 5187-5198 (2009)
  115. Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. Puzanov I, Amaravadi RK, McArthur GA, Flaherty KT, Chapman PB, Sosman JA, Ribas A, Shackleton M, Hwu P, Chmielowski B, Nolop KB, Lin PS, Kim KB. Eur J Cancer 51 1435-1443 (2015)
  116. Management of conjunctival malignant melanoma: a review and update. Wong JR, Nanji AA, Galor A, Karp CL. Expert Rev Ophthalmol 9 185-204 (2014)
  117. A MEK-independent role for CRAF in mitosis and tumor progression. Mielgo A, Seguin L, Huang M, Camargo MF, Anand S, Franovic A, Weis SM, Advani SJ, Murphy EA, Cheresh DA. Nat Med 17 1641-1645 (2011)
  118. Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia. Yaktapour N, Übelhart R, Schüler J, Aumann K, Dierks C, Burger M, Pfeifer D, Jumaa H, Veelken H, Brummer T, Zirlik K. Blood 122 1621-1633 (2013)
  119. MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS-, and NF1-Mutant Melanomas. Maertens O, Kuzmickas R, Manchester HE, Emerson CE, Gavin AG, Guild CJ, Wong TC, De Raedt T, Bowman-Colin C, Hatchi E, Garraway LA, Flaherty KT, Pathania S, Elledge SJ, Cichowski K. Cancer Discov 9 526-545 (2019)
  120. Sensitive detection of BRAF V600E mutation by Amplification Refractory Mutation System (ARMS)-PCR. Huang T, Zhuge J, Zhang WW. Biomark Res 1 3 (2013)
  121. The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance. Sale MJ, Cook SJ. Biochem J 450 285-294 (2013)
  122. Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. Li S, Song Y, Quach C, Guo H, Jang GB, Maazi H, Zhao S, Sands NA, Liu Q, In GK, Peng D, Yuan W, Machida K, Yu M, Akbari O, Hagiya A, Yang Y, Punj V, Tang L, Liang C. Nat Commun 10 1693 (2019)
  123. AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma. Hu W, Jin L, Jiang CC, Long GV, Scolyer RA, Wu Q, Zhang XD, Mei Y, Wu M. Cell Death Dis 4 e914 (2013)
  124. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. Pettirossi V, Santi A, Imperi E, Russo G, Pucciarini A, Bigerna B, Schiavoni G, Fortini E, Spanhol-Rosseto A, Sportoletti P, Mannucci R, Martelli MP, Klein-Hitpass L, Falini B, Tiacci E. Blood 125 1207-1216 (2015)
  125. BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation. Young K, Minchom A, Larkin J. Future Oncol 8 499-507 (2012)
  126. Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells. Martin S, Dudek-Perić AM, Maes H, Garg AD, Gabrysiak M, Demirsoy S, Swinnen JV, Agostinis P. Biochem Pharmacol 93 290-304 (2015)
  127. Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. Nehs MA, Nucera C, Nagarkatti SS, Sadow PM, Morales-Garcia D, Hodin RA, Parangi S. Endocrinology 153 985-994 (2012)
  128. B-Raf Inhibition in the Clinic: Present and Future. Fiskus W, Mitsiades N. Annu Rev Med 67 29-43 (2016)
  129. FOXD3 regulates migration properties and Rnd3 expression in melanoma cells. Katiyar P, Aplin AE. Mol Cancer Res 9 545-552 (2011)
  130. Targeting sphingosine kinase-1 to inhibit melanoma. Madhunapantula SV, Hengst J, Gowda R, Fox TE, Yun JK, Robertson GP. Pigment Cell Melanoma Res 25 259-274 (2012)
  131. Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy. Mohana-Kumaran N, Hill DS, Allen JD, Haass NK. Pigment Cell Melanoma Res 27 525-539 (2014)
  132. (V600E)BRAF promotes invasiveness of thyroid cancer cells by decreasing E-cadherin expression through a Snail-dependent mechanism. Baquero P, Sánchez-Hernández I, Jiménez-Mora E, Orgaz JL, Jiménez B, Chiloeches A. Cancer Lett 335 232-241 (2013)
  133. Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents. Khan MK, Khan N, Almasan A, Macklis R. Onco Targets Ther 4 137-148 (2011)
  134. Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma. Oliveira CS, de Bock CE, Molloy TJ, Sadeqzadeh E, Geng XY, Hersey P, Zhang XD, Thorne RF. BMC Cancer 14 630 (2014)
  135. The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). Xing J, Liu R, Xing M, Trink B. Biochem Biophys Res Commun 404 958-962 (2011)
  136. Wnt/β-catenin and MAPK signaling: allies and enemies in different battlefields. Guardavaccaro D, Clevers H. Sci Signal 5 pe15 (2012)
  137. Molecular Mechanism of Protein Kinase Recognition and Sorting by the Hsp90 Kinome-Specific Cochaperone Cdc37. Keramisanou D, Aboalroub A, Zhang Z, Liu W, Marshall D, Diviney A, Larsen RW, Landgraf R, Gelis I. Mol Cell 62 260-271 (2016)
  138. Pilomyxoid astrocytoma treated successfully with vemurafenib. Skrypek M, Foreman N, Guillaume D, Moertel C. Pediatr Blood Cancer 61 2099-2100 (2014)
  139. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor. Kaplan FM, Kugel CH, Dadpey N, Shao Y, Abel EV, Aplin AE. J Biol Chem 287 41797-41807 (2012)
  140. BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation. Silva JM, Bulman C, McMahon M. Mol Cancer Res 12 447-463 (2014)
  141. Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition. Kirkpatrick DS, Bustos DJ, Dogan T, Chan J, Phu L, Young A, Friedman LS, Belvin M, Song Q, Bakalarski CE, Hoeflich KP. Proc Natl Acad Sci U S A 110 19426-19431 (2013)
  142. Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. Smith MP, Rowling EJ, Miskolczi Z, Ferguson J, Spoerri L, Haass NK, Sloss O, McEntegart S, Arozarena I, von Kriegsheim A, Rodriguez J, Brunton H, Kmarashev J, Levesque MP, Dummer R, Frederick DT, Andrews MC, Cooper ZA, Flaherty KT, Wargo JA, Wellbrock C. EMBO Mol Med 9 1011-1029 (2017)
  143. Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Bottos A, Martini M, Di Nicolantonio F, Comunanza V, Maione F, Minassi A, Appendino G, Bussolino F, Bardelli A. Proc Natl Acad Sci U S A 109 E353-9 (2012)
  144. Ipilimumab in advanced melanoma: reports of long-lasting responses. Farolfi A, Ridolfi L, Guidoboni M, Nicoletti SV, Piciucchi S, Valmorri L, Costantini M, Scarpi E, Amadori D, Ridolfi R. Melanoma Res 22 263-270 (2012)
  145. Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032. Jenkins MH, Steinberg SM, Alexander MP, Fisher JL, Ernstoff MS, Turk MJ, Mullins DW, Brinckerhoff CE. Pigment Cell Melanoma Res 27 495-501 (2014)
  146. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells. Wu CP, Sim HM, Huang YH, Liu YC, Hsiao SH, Cheng HW, Li YQ, Ambudkar SV, Hsu SC. Biochem Pharmacol 85 325-334 (2013)
  147. A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma. Grippo JF, Zhang W, Heinzmann D, Yang KH, Wong J, Joe AK, Munster P, Sarapa N, Daud A. Cancer Chemother Pharmacol 73 103-111 (2014)
  148. BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells. Goulielmaki M, Koustas E, Moysidou E, Vlassi M, Sasazuki T, Shirasawa S, Zografos G, Oikonomou E, Pintzas A. Oncotarget 7 9188-9221 (2016)
  149. BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor. Ozer HG, El-Gamal D, Powell B, Hing ZA, Blachly JS, Harrington B, Mitchell S, Grieselhuber NR, Williams K, Lai TH, Alinari L, Baiocchi RA, Brinton L, Baskin E, Cannon M, Beaver L, Goettl VM, Lucas DM, Woyach JA, Sampath D, Lehman AM, Yu L, Zhang J, Ma Y, Zhang Y, Spevak W, Shi S, Severson P, Shellooe R, Carias H, Tsang G, Dong K, Ewing T, Marimuthu A, Tantoy C, Walters J, Sanftner L, Rezaei H, Nespi M, Matusow B, Habets G, Ibrahim P, Zhang C, Mathé EA, Bollag G, Byrd JC, Lapalombella R. Cancer Discov 8 458-477 (2018)
  150. Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors. Whittaker SR, Cowley GS, Wagner S, Luo F, Root DE, Garraway LA. Mol Cancer Ther 14 2700-2711 (2015)
  151. Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma. Fang M, Hutchinson L, Deng A, Green MR. Proc Natl Acad Sci U S A 113 1250-1255 (2016)
  152. Modulation of matrix elasticity with PEG hydrogels to study melanoma drug responsiveness. Tokuda EY, Leight JL, Anseth KS. Biomaterials 35 4310-4318 (2014)
  153. Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance. Oikonomou E, Koc M, Sourkova V, Andera L, Pintzas A. PLoS One 6 e21632 (2011)
  154. Therapeutic implications of targeting the PI3Kinase/AKT/mTOR signaling module in melanoma therapy. Jazirehi AR, Wenn PB, Damavand M. Am J Cancer Res 2 178-191 (2012)
  155. Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor. Zhang C, Ibrahim PN, Zhang J, Burton EA, Habets G, Zhang Y, Powell B, West BL, Matusow B, Tsang G, Shellooe R, Carias H, Nguyen H, Marimuthu A, Zhang KY, Oh A, Bremer R, Hurt CR, Artis DR, Wu G, Nespi M, Spevak W, Lin P, Nolop K, Hirth P, Tesch GH, Bollag G. Proc Natl Acad Sci U S A 110 5689-5694 (2013)
  156. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor. Caporali S, Alvino E, Lacal PM, Levati L, Giurato G, Memoli D, Caprini E, Antonini Cappellini GC, D'Atri S. Int J Oncol 49 1164-1174 (2016)
  157. Theranostics of malignant melanoma with 64CuCl2. Qin C, Liu H, Chen K, Hu X, Ma X, Lan X, Zhang Y, Cheng Z. J Nucl Med 55 812-817 (2014)
  158. Comment Where does the combination of sorafenib and interferon in renal cell carcinoma stand? Flaherty KT. Cancer 116 4-7 (2010)
  159. Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma. Lázár V, Ecsedi S, Szöllosi AG, Tóth R, Vízkeleti L, Rákosy Z, Bégány A, Adány R, Balázs M. Mod Pathol 22 1367-1378 (2009)
  160. Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy. Mitsiades N, Chew SA, He B, Riechardt AI, Karadedou T, Kotoula V, Poulaki V. Invest Ophthalmol Vis Sci 52 7248-7255 (2011)
  161. In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors. Basile KJ, Abel EV, Dadpey N, Hartsough EJ, Fortina P, Aplin AE. Cancer Res 73 7101-7110 (2013)
  162. MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma. Wood KC, Konieczkowski DJ, Johannessen CM, Boehm JS, Tamayo P, Botvinnik OB, Mesirov JP, Hahn WC, Root DE, Garraway LA, Sabatini DM. Sci Signal 5 rs4 (2012)
  163. Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas. Kim IJ, Quigley D, To MD, Pham P, Lin K, Jo B, Jen KY, Raz D, Kim J, Mao JH, Jablons D, Balmain A. Nat Commun 4 1701 (2013)
  164. Structural basis for the inhibition of HSP70 and DnaK chaperones by small-molecule targeting of a C-terminal allosteric pocket. Leu JI, Zhang P, Murphy ME, Marmorstein R, George DL. ACS Chem Biol 9 2508-2516 (2014)
  165. Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer. Nehs MA, Nagarkatti S, Nucera C, Hodin RA, Parangi S. Surgery 148 1154-62; discussion 1162 (2010)
  166. Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma. Fowles JS, Denton CL, Gustafson DL. Vet Comp Oncol 13 288-304 (2015)
  167. JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma. Titz B, Lomova A, Le A, Hugo W, Kong X, Ten Hoeve J, Friedman M, Shi H, Moriceau G, Song C, Hong A, Atefi M, Li R, Komisopoulou E, Ribas A, Lo RS, Graeber TG. Cell Discov 2 16028 (2016)
  168. AMPK promotes tolerance to Ras pathway inhibition by activating autophagy. Sanduja S, Feng Y, Mathis RA, Sokol ES, Reinhardt F, Halaban R, Gupta PB. Oncogene 35 5295-5303 (2016)
  169. Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas. Mimeault M, Batra SK. World J Clin Oncol 3 32-42 (2012)
  170. Parallel in vivo and in vitro melanoma RNAi dropout screens reveal synthetic lethality between hypoxia and DNA damage response inhibition. Possik PA, Müller J, Gerlach C, Kenski JC, Huang X, Shahrabi A, Krijgsman O, Song JY, Smit MA, Gerritsen B, Lieftink C, Kemper K, Michaut M, Beijersbergen RL, Wessels L, Schumacher TN, Peeper DS. Cell Rep 9 1375-1386 (2014)
  171. RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition. Jin T, Lavoie H, Sahmi M, David M, Hilt C, Hammell A, Therrien M. Nat Commun 8 1211 (2017)
  172. Letter Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes. Villaseñor AG, Kondru R, Ho H, Wang S, Papp E, Shaw D, Barnett JW, Browner MF, Kuglstatter A. Chem Biol Drug Des 73 466-470 (2009)
  173. Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma. Fisher R, Larkin J. Cancer Manag Res 4 243-252 (2012)
  174. A growing family: adding mutated Erbb4 as a novel cancer target. Rudloff U, Samuels Y. Cell Cycle 9 1487-1503 (2010)
  175. A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. Dugo M, Nicolini G, Tragni G, Bersani I, Tomassetti A, Colonna V, Del Vecchio M, De Braud F, Canevari S, Anichini A, Sensi M. Oncotarget 6 5118-5133 (2015)
  176. Lessons from next-generation sequencing analysis in hematological malignancies. Braggio E, Egan JB, Fonseca R, Stewart AK. Blood Cancer J 3 e127 (2013)
  177. Multifunctional bioscaffolds for 3D culture of melanoma cells reveal increased MMP activity and migration with BRAF kinase inhibition. Leight JL, Tokuda EY, Jones CE, Lin AJ, Anseth KS. Proc Natl Acad Sci U S A 112 5366-5371 (2015)
  178. RAF inhibition overcomes resistance to TRAIL-induced apoptosis in melanoma cells. Berger A, Quast SA, Plötz M, Kuhn NF, Trefzer U, Eberle J. J Invest Dermatol 134 430-440 (2014)
  179. Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/β-catenin activation. Conrad WH, Swift RD, Biechele TL, Kulikauskas RM, Moon RT, Chien AJ. Cell Cycle 11 3724-3730 (2012)
  180. Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways. Tassi E, Zanon M, Vegetti C, Molla A, Bersani I, Perotti V, Pennati M, Zaffaroni N, Milella M, Ferrone S, Carlo-Stella C, Gianni AM, Mortarini R, Anichini A. Clin Cancer Res 18 3316-3327 (2012)
  181. Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer. Vanden Borre P, Gunda V, McFadden DG, Sadow PM, Varmeh S, Bernasconi M, Parangi S. Oncotarget 5 3996-4010 (2014)
  182. Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma. Qin Y, Roszik J, Chattopadhyay C, Hashimoto Y, Liu C, Cooper ZA, Wargo JA, Hwu P, Ekmekcioglu S, Grimm EA. Mol Cancer Ther 15 2442-2454 (2016)
  183. Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma. Benamar M, Guessous F, Du K, Corbett P, Obeid J, Gioeli D, Slingluff CL, Abbas T. EBioMedicine 10 85-100 (2016)
  184. Quantitative analysis of [11C]-erlotinib PET demonstrates specific binding for activating mutations of the EGFR kinase domain. Petrulli JR, Sullivan JM, Zheng MQ, Bennett DC, Charest J, Huang Y, Morris ED, Contessa JN. Neoplasia 15 1347-1353 (2013)
  185. The three-dimensional human skin reconstruct model: a tool to study normal skin and melanoma progression. Li L, Fukunaga-Kalabis M, Herlyn M. J Vis Exp (2011)
  186. Therapeutic Implications of Targeting AKT Signaling in Melanoma. Madhunapantula SV, Robertson GP. Enzyme Res 2011 327923 (2011)
  187. Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells. Beaumont KA, Hill DS, Daignault SM, Lui GYL, Sharp DM, Gabrielli B, Weninger W, Haass NK. J Invest Dermatol 136 1479-1489 (2016)
  188. C-RAF mutations confer resistance to RAF inhibitors. Antony R, Emery CM, Sawyer AM, Garraway LA. Cancer Res 73 4840-4851 (2013)
  189. Consistency in large pharmacogenomic studies. Geeleher P, Gamazon ER, Seoighe C, Cox NJ, Huang RS. Nature 540 E1-E2 (2016)
  190. Evaluation of LMP1 of Epstein-Barr virus as a therapeutic target by its inhibition. Hannigan A, Wilson JB. Mol Cancer 9 184 (2010)
  191. Transgenic expression of oncogenic BRAF induces loss of stem cells in the mouse intestine, which is antagonized by β-catenin activity. Riemer P, Sreekumar A, Reinke S, Rad R, Schäfer R, Sers C, Bläker H, Herrmann BG, Morkel M. Oncogene 34 3164-3175 (2015)
  192. A beta-camera integrated with a microfluidic chip for radioassays based on real-time imaging of glycolysis in small cell populations. Vu NT, Yu ZT, Comin-Anduix B, Søndergaard JN, Silverman RW, Chang CY, Ribas A, Tseng HR, Chatziioannou AF. J Nucl Med 52 815-821 (2011)
  193. AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment. Caputo E, Miceli R, Motti ML, Taté R, Fratangelo F, Botti G, Mozzillo N, Carriero MV, Cavalcanti E, Palmieri G, Ciliberto G, Pirozzi G, Ascierto PA. J Transl Med 12 216 (2014)
  194. B-Raf associates with and activates the NHE1 isoform of the Na+/H+ exchanger. Karki P, Li X, Schrama D, Fliegel L. J Biol Chem 286 13096-13105 (2011)
  195. Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy. Bradish JR, Richey JD, Post KM, Meehan K, Sen JD, Malek AJ, Katona TM, Warren S, Logan TF, Fecher LA, Cheng L. Mod Pathol 28 480-486 (2015)
  196. Genetic and functional characterization of putative Ras/Raf interaction inhibitors in C. elegans and mammalian cells. González-Pérez V, Reiner DJ, Alan JK, Mitchell C, Edwards LJ, Khazak V, Der CJ, Cox AD. J Mol Signal 5 2 (2010)
  197. Hsp90·Cdc37 Complexes with Protein Kinases Form Cooperatively with Multiple Distinct Interaction Sites. Eckl JM, Scherr MJ, Freiburger L, Daake MA, Sattler M, Richter K. J Biol Chem 290 30843-30854 (2015)
  198. Identification of BRAF inhibitors through in silico screening. Luo C, Xie P, Marmorstein R. J Med Chem 51 6121-6127 (2008)
  199. Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling. Kyula JN, Khan AA, Mansfield D, Karapanagiotou EM, McLaughlin M, Roulstone V, Zaidi S, Pencavel T, Touchefeu Y, Seth R, Chen NG, Yu YA, Zhang Q, Melcher AA, Vile RG, Pandha HS, Ajaz M, Szalay AA, Harrington KJ. Oncogene 33 1700-1712 (2014)
  200. Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitor. Jazirehi AR, Nazarian R, Torres-Collado AX, Economou JS. Am J Clin Exp Immunol 3 43-56 (2014)
  201. MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction. Asmussen J, Lasater EA, Tajon C, Oses-Prieto J, Jun YW, Taylor BS, Burlingame A, Craik CS, Shah NP. Cancer Discov 4 200-215 (2014)
  202. MicroRNA-26a inhibits the growth and invasiveness of malignant melanoma and directly targets on MITF gene. Qian H, Yang C, Yang Y. Cell Death Discov 3 17028 (2017)
  203. The raf inhibitor paradox: unexpected consequences of targeted drugs. Cox AD, Der CJ. Cancer Cell 17 221-223 (2010)
  204. Virtual fragment screening on GPCRs: a case study on dopamine D3 and histamine H4 receptors. Vass M, Schmidt É, Horti F, Keserű GM. Eur J Med Chem 77 38-46 (2014)
  205. Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling. Chien AJ, Haydu LE, Biechele TL, Kulikauskas RM, Rizos H, Kefford RF, Scolyer RA, Moon RT, Long GV. PLoS One 9 e94748 (2014)
  206. Targeting oncogenic BRAF in human cancer. Pratilas CA, Xing F, Solit DB. Curr Top Microbiol Immunol 355 83-98 (2012)
  207. Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth. Ji Z, Kumar R, Taylor M, Rajadurai A, Marzuka-Alcalá A, Chen YE, Njauw CN, Flaherty K, Jönsson G, Tsao H. Clin Cancer Res 19 4383-4391 (2013)
  208. 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer. McKinley ET, Smith RA, Zhao P, Fu A, Saleh SA, Uddin MI, Washington MK, Coffey RJ, Manning HC. J Nucl Med 54 424-430 (2013)
  209. A switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition. Klein RM, Higgins PJ. Mol Cancer 10 114 (2011)
  210. BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance. Sullivan RJ, Flaherty KT. J Skin Cancer 2011 423239 (2011)
  211. Interferon α/β Enhances the Cytotoxic Response of MEK Inhibition in Melanoma. Litvin O, Schwartz S, Wan Z, Schild T, Rocco M, Oh NL, Chen BJ, Goddard N, Pratilas C, Pe'er D. Mol Cell 57 784-796 (2015)
  212. Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma. Haak AJ, Appleton KM, Lisabeth EM, Misek SA, Ji Y, Wade SM, Bell JL, Rockwell CE, Airik M, Krook MA, Larsen SD, Verhaegen M, Lawlor ER, Neubig RR. Mol Cancer Ther 16 193-204 (2017)
  213. Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships. Wenglowsky S, Ahrendt KA, Buckmelter AJ, Feng B, Gloor SL, Gradl S, Grina J, Hansen JD, Laird ER, Lunghofer P, Mathieu S, Moreno D, Newhouse B, Ren L, Risom T, Rudolph J, Seo J, Sturgis HL, Voegtli WC, Wen Z. Bioorg Med Chem Lett 21 5533-5537 (2011)
  214. Structural insights into binding of inhibitors to soluble epoxide hydrolase gained by fragment screening and X-ray crystallography. Amano Y, Yamaguchi T, Tanabe E. Bioorg Med Chem 22 2427-2434 (2014)
  215. Letter A somatic mutation of the KEAP1 gene in malignant melanoma is involved in aberrant NRF2 activation and an increase in intrinsic drug resistance. Miura S, Shibazaki M, Kasai S, Yasuhira S, Watanabe A, Inoue T, Kageshita Y, Tsunoda K, Takahashi K, Akasaka T, Masuda T, Maesawa C. J Invest Dermatol 134 553-556 (2014)
  216. BRAF inhibitors in clinical oncology. Morris V, Kopetz S. F1000Prime Rep 5 11 (2013)
  217. Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAFV600E melanoma. Ngiow SF, Meeth KM, Stannard K, Barkauskas DS, Bollag G, Bosenberg M, Smyth MJ. Oncoimmunology 5 e1089381 (2016)
  218. Identification of TFG (TRK-fused gene) as a putative metastatic melanoma tumor suppressor gene. Dutton-Regester K, Aoude LG, Nancarrow DJ, Stark MS, O'Connor L, Lanagan C, Pupo GM, Tembe V, Carter CD, O'Rourke M, Scolyer RA, Mann GJ, Schmidt CW, Herington A, Hayward NK. Genes Chromosomes Cancer 51 452-461 (2012)
  219. Immunoassay-based proteome profiling of 24 pancreatic cancer cell lines. Alhamdani MS, Youns M, Buchholz M, Gress TM, Beckers MC, Maréchal D, Bauer A, Schröder C, Hoheisel JD. J Proteomics 75 3747-3759 (2012)
  220. Negative regulation of RAF kinase activity by ATP is overcome by 14-3-3-induced dimerization. Liau NPD, Wendorff TJ, Quinn JG, Steffek M, Phung W, Liu P, Tang J, Irudayanathan FJ, Izadi S, Shaw AS, Malek S, Hymowitz SG, Sudhamsu J. Nat Struct Mol Biol 27 134-141 (2020)
  221. Selenium Inhibits Metastasis of Murine Melanoma Cells through the Induction of Cell Cycle Arrest and Cell Death. Song H, Hur I, Park HJ, Nam J, Park GB, Kong KH, Hwang YM, Kim YS, Cho DH, Lee WJ, Hur DY. Immune Netw 9 236-242 (2009)
  222. A peptide-based positron emission tomography probe for in vivo detection of caspase activity in apoptotic cells. Hight MR, Cheung YY, Nickels ML, Dawson ES, Zhao P, Saleh S, Buck JR, Tang D, Washington MK, Coffey RJ, Manning HC. Clin Cancer Res 20 2126-2135 (2014)
  223. Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas. Zhang J, Yao TW, Hashizume R, Hariono S, Barkovich KJ, Fan QW, Prados M, James CD, Weiss WA, Nicolaides T. J Neurooncol 131 495-505 (2017)
  224. Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression. Cicchini M, Buza EL, Sagal KM, Gudiel AA, Durham AC, Feldser DM. Cell Rep 18 1958-1969 (2017)
  225. Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes. Skora AD, Douglass J, Hwang MS, Tam AJ, Blosser RL, Gabelli SB, Cao J, Diaz LA, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S. Proc Natl Acad Sci U S A 112 9967-9972 (2015)
  226. Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAFV600E-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair. Robb R, Yang L, Shen C, Wolfe AR, Webb A, Zhang X, Vedaie M, Saji M, Jhiang S, Ringel MD, Williams TM. Clin Cancer Res 25 4749-4760 (2019)
  227. NF-κB Regulation of c-FLIP Promotes TNFα-Mediated RAF Inhibitor Resistance in Melanoma. Shao Y, Le K, Cheng H, Aplin AE. J Invest Dermatol 135 1839-1848 (2015)
  228. Network-based co-expression analysis for exploring the potential diagnostic biomarkers of metastatic melanoma. Wang LX, Li Y, Chen GZ. PLoS One 13 e0190447 (2018)
  229. P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells. Babagana M, Johnson S, Slabodkin H, Bshara W, Morrison C, Kandel ES. Mol Carcinog 56 1515-1525 (2017)
  230. 1,4-dihydropyrazolo[4,3-d]imidazole phenyl derivatives: a novel type II Raf kinase inhibitors. Yu H, Jung Y, Kim H, Lee J, Oh CH, Yoo KH, Sim T, Hah JM. Bioorg Med Chem Lett 20 3805-3808 (2010)
  231. Autophagy-Dependent Survival of Mutant B-Raf Melanoma Cells Selected for Resistance to Apoptosis Induced by Inhibitors against Oncogenic B-Raf. Ahn JH, Lee M. Biomol Ther (Seoul) 21 114-120 (2013)
  232. Aza-tryptamine substrates in monoterpene indole alkaloid biosynthesis. Lee HY, Yerkes N, O'Connor SE. Chem Biol 16 1225-1229 (2009)
  233. Detection of BRAF V600 mutations in melanoma: evaluation of concordance between the Cobas® 4800 BRAF V600 mutation test and the methods used in French National Cancer Institute (INCa) platforms in a real-life setting. Mourah S, Denis MG, Narducci FE, Solassol J, Merlin JL, Sabourin JC, Scoazec JY, Ouafik L, Emile JF, Heller R, Souvignet C, Bergougnoux L, Merlio JP. PLoS One 10 e0120232 (2015)
  234. GATA2 is epigenetically repressed in human and mouse lung tumors and is not requisite for survival of KRAS mutant lung cancer. Tessema M, Yingling CM, Snider AM, Do K, Juri DE, Picchi MA, Zhang X, Liu Y, Leng S, Tellez CS, Belinsky SA. J Thorac Oncol 9 784-793 (2014)
  235. Genetics of melanoma. Wangari-Talbot J, Chen S. Front Genet 3 330 (2012)
  236. Mutant B-RAF regulates a Rac-dependent cadherin switch in melanoma. Monaghan-Benson E, Burridge K. Oncogene 32 4836-4844 (2013)
  237. Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs. Jazirehi AR, Economou JS. Mol Cancer Ther 11 1332-1341 (2012)
  238. Summary statement: utility of molecular marker testing in thyroid cancer. Yip L, Kebebew E, Milas M, Carty SE, Fahey TJ, Parangi S, Zeiger MA, Nikiforov YE. Surgery 148 1313-1315 (2010)
  239. Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma. Zecena H, Tveit D, Wang Z, Farhat A, Panchal P, Liu J, Singh SJ, Sanghera A, Bainiwal A, Teo SY, Meyskens FL, Liu-Smith F, Filipp FV. BMC Syst Biol 12 33 (2018)
  240. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression. Phadke MS, Sini P, Smalley KS. Mol Cancer Ther 14 1354-1364 (2015)
  241. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. Del Curatolo A, Conciatori F, Cesta Incani U, Bazzichetto C, Falcone I, Corbo V, D'Agosto S, Eramo A, Sette G, Sperduti I, De Luca T, Marabese M, Shirasawa S, De Maria R, Scarpa A, Broggini M, Del Bufalo D, Cognetti F, Milella M, Ciuffreda L. J Exp Clin Cancer Res 37 140 (2018)
  242. Fragment Hits: What do They Look Like and How do They Bind? Giordanetto F, Jin C, Willmore L, Feher M, Shaw DE. J Med Chem 62 3381-3394 (2019)
  243. High-throughput fragment screening by affinity LC-MS. Duong-Thi MD, Bergström M, Fex T, Isaksson R, Ohlson S. J Biomol Screen 18 160-171 (2013)
  244. IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis. Perimenis P, Galaris A, Voulgari A, Prassa M, Pintzas A. BMC Cancer 16 624 (2016)
  245. In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways. Daphu I, Horn S, Stieber D, Varughese JK, Spriet E, Dale HA, Skaftnesmo KO, Bjerkvig R, Thorsen F. Int J Mol Sci 15 8773-8794 (2014)
  246. Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line. Peng W, Hu J, Zhu XD, Liu X, Wang CC, Li WH, Chen ZY. Tumour Biol 35 2983-2988 (2014)
  247. Letter The use of virtual screening and differential scanning fluorimetry for the rapid identification of fragments active against MEK1. Amaning K, Lowinski M, Vallee F, Steier V, Marcireau C, Ugolini A, Delorme C, Foucalt F, McCort G, Derimay N, Andouche C, Vougier S, Llopart S, Halland N, Rak A. Bioorg Med Chem Lett 23 3620-3626 (2013)
  248. Toward personalized cancer nanomedicine - past, present, and future. Stegh AH. Integr Biol (Camb) 5 48-65 (2013)
  249. A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors. Aloia A, Müllhaupt D, Chabbert CD, Eberhart T, Flückiger-Mangual S, Vukolic A, Eichhoff O, Irmisch A, Alexander LT, Scibona E, Frederick DT, Miao B, Tian T, Cheng C, Kwong LN, Wei Z, Sullivan RJ, Boland GM, Herlyn M, Flaherty KT, Zamboni N, Dummer R, Zhang G, Levesque MP, Krek W, Kovacs WJ. Clin Cancer Res 25 6852-6867 (2019)
  250. A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. Mooradian MJ, Reuben A, Prieto PA, Hazar-Rethinam M, Frederick DT, Nadres B, Piris A, Juneja V, Cooper ZA, Sharpe AH, Corcoran RB, Flaherty KT, Lawrence DP, Wargo JA, Sullivan RJ. Oncoimmunology 7 e1423172 (2018)
  251. CXCR3 signaling in BRAFWT melanoma increases IL-8 expression and tumorigenicity. Jenkins MH, Brinckerhoff CE, Mullins DW. PLoS One 10 e0121140 (2015)
  252. Computational fragment-based screening using RosettaLigand: the SAMPL3 challenge. Kumar A, Zhang KY. J Comput Aided Mol Des 26 603-616 (2012)
  253. Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment. Smalley KS, Flaherty KT. Future Oncol 5 775-778 (2009)
  254. Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization. Kong X, Qin J, Li Z, Vultur A, Tong L, Feng E, Rajan G, Liu S, Lu J, Liang Z, Zheng M, Zhu W, Jiang H, Herlyn M, Liu H, Marmorstein R, Luo C. Org Biomol Chem 10 7402-7417 (2012)
  255. Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines. Lee J, Kim H, Yu H, Chung JY, Oh CH, Yoo KH, Sim T, Hah JM. Bioorg Med Chem Lett 20 1573-1577 (2010)
  256. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. Yao TW, Zhang J, Prados M, Weiss WA, James CD, Nicolaides T. Oncotarget 6 21993-22005 (2015)
  257. Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM. Rohrbeck L, Gong JN, Lee EF, Kueh AJ, Behren A, Tai L, Lessene G, Huang DC, Fairlie WD, Strasser A, Herold MJ. Cell Death Differ 23 2054-2062 (2016)
  258. Knowledge-based design of 7-azaindoles as selective B-Raf inhibitors. Tang J, Hamajima T, Nakano M, Sato H, Dickerson SH, Lackey KE. Bioorg Med Chem Lett 18 4610-4614 (2008)
  259. Molecular dynamics simulations and modelling of the residue interaction networks in the BRAF kinase complexes with small molecule inhibitors: probing the allosteric effects of ligand-induced kinase dimerization and paradoxical activation. Verkhivker GM. Mol Biosyst 12 3146-3165 (2016)
  260. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors. Wenglowsky S, Moreno D, Laird ER, Gloor SL, Ren L, Risom T, Rudolph J, Sturgis HL, Voegtli WC. Bioorg Med Chem Lett 22 6237-6241 (2012)
  261. X-ray structure of p38α bound to TAK-715: comparison with three classic inhibitors. Azevedo R, van Zeeland M, Raaijmakers H, Kazemier B, de Vlieg J, Oubrie A. Acta Crystallogr D Biol Crystallogr 68 1041-1050 (2012)
  262. A Naturally Generated Decoy of the Prostate Apoptosis Response-4 Protein Overcomes Therapy Resistance in Tumors. Hebbar N, Burikhanov R, Shukla N, Qiu S, Zhao Y, Elenitoba-Johnson KSJ, Rangnekar VM. Cancer Res 77 4039-4050 (2017)
  263. A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice. Feng JH, Nakagawa-Goto K, Lee KH, Shyur LF. Mol Cancer Ther 15 1163-1176 (2016)
  264. B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells. Roos WP, Quiros S, Krumm A, Merz S, Switzeny OJ, Christmann M, Loquai C, Kaina B. Oncotarget 5 12607-12620 (2014)
  265. Biological and molecular effects of small molecule kinase inhibitors on low-passage human colorectal cancer cell lines. Lange F, Franz B, Maletzki C, Linnebacher M, Hühns M, Jaster R. Biomed Res Int 2014 568693 (2014)
  266. CADM1 is a TWIST1-regulated suppressor of invasion and survival. Hartsough EJ, Weiss MB, Heilman SA, Purwin TJ, Kugel CH, Rosenbaum SR, Erkes DA, Tiago M, HooKim K, Chervoneva I, Aplin AE. Cell Death Dis 10 281 (2019)
  267. CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer. Wu C, Bekaii-Saab T. Chemother Res Pract 2012 359041 (2012)
  268. Creating novel activated factor XI inhibitors through fragment based lead generation and structure aided drug design. Fjellström O, Akkaya S, Beisel HG, Eriksson PO, Erixon K, Gustafsson D, Jurva U, Kang D, Karis D, Knecht W, Nerme V, Nilsson I, Olsson T, Redzic A, Roth R, Sandmark J, Tigerström A, Öster L. PLoS One 10 e0113705 (2015)
  269. Current research and development of chemotherapeutic agents for melanoma. Hsan KM, Chen CC, Shyur LF. Cancers (Basel) 2 397-419 (2010)
  270. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying vemurafenib in human plasma. Nijenhuis CM, Rosing H, Schellens JH, Beijnen JH. J Pharm Biomed Anal 88 630-635 (2014)
  271. Discovery of biarylaminoquinazolines as novel tubulin polymerization inhibitors. Marzaro G, Coluccia A, Ferrarese A, Brun P, Castagliuolo I, Conconi MT, La Regina G, Bai R, Silvestri R, Hamel E, Chilin A. J Med Chem 57 4598-4605 (2014)
  272. Congress Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. Ascierto PA, Grimaldi AM, Anderson AC, Bifulco C, Cochran A, Garbe C, Eggermont AM, Faries M, Ferrone S, Gershenwald JE, Gajewski TF, Halaban R, Hodi FS, Kefford R, Kirkwood JM, Larkin J, Leachman S, Maio M, Marais R, Masucci G, Melero I, Palmieri G, Puzanov I, Ribas A, Saenger Y, Schilling B, Seliger B, Stroncek D, Sullivan R, Testori A, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. J Transl Med 12 277 (2014)
  273. Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma? Nijenhuis CM, Haanen JB, Schellens JH, Beijnen JH. Cancer Treat Rev 39 305-312 (2013)
  274. Large scale meta-analysis of fragment-based screening campaigns: privileged fragments and complementary technologies. Kutchukian PS, Wassermann AM, Lindvall MK, Wright SK, Ottl J, Jacob J, Scheufler C, Marzinzik A, Brooijmans N, Glick M. J Biomol Screen 20 588-596 (2015)
  275. Microphthalmia-associated transcription factor suppresses invasion by reducing intracellular GTP pools. Bianchi-Smiraglia A, Bagati A, Fink EE, Moparthy S, Wawrzyniak JA, Marvin EK, Battaglia S, Jowdy P, Kolesnikova M, Foley CE, Berman AE, Kozlova NI, Lipchick BC, Paul-Rosner LM, Bshara W, Ackroyd JJ, Shewach DS, Nikiforov MA. Oncogene 36 84-96 (2017)
  276. Oncogenic BRAF inhibitor UAI-201 induces cell cycle arrest and autophagy in BRAF mutant glioma cells. Ahn JH, Lee YW, Ahn SK, Lee M. Life Sci 104 38-46 (2014)
  277. Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine. Warthaka M, Adelmann CH, Kaoud TS, Edupuganti R, Yan C, Johnson WH, Ferguson S, Tavares CD, Pence LJ, Anslyn EV, Ren P, Tsai KY, Dalby KN. ACS Med Chem Lett 6 47-52 (2015)
  278. Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling. Jung KY, Samadani R, Chauhan J, Nevels K, Yap JL, Zhang J, Worlikar S, Lanning ME, Chen L, Ensey M, Shukla S, Salmo R, Heinzl G, Gordon C, Dukes T, MacKerell AD, Shapiro P, Fletcher S. Org Biomol Chem 11 3706-3732 (2013)
  279. Synchronous BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity. Gadiot J, Hooijkaas AI, Deken MA, Blank CU. Onco Targets Ther 6 1649-1658 (2013)
  280. The most common RNF43 mutant G659Vfs*41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis. Tu J, Park S, Yu W, Zhang S, Wu L, Carmon K, Liu QJ. Sci Rep 9 18557 (2019)
  281. UbFluor: A Mechanism-Based Probe for HECT E3 Ligases. Krist DT, Park S, Boneh GH, Rice SE, Statsyuk AV. Chem Sci 7 5587-5595 (2016)
  282. A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF. Whittaker S, Ménard D, Kirk R, Ogilvie L, Hedley D, Zambon A, Lopes F, Preece N, Manne H, Rana S, Lambros M, Reis-Filho JS, Marais R, Springer CJ. Cancer Res 70 8036-8044 (2010)
  283. A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma. Goldinger SM, Rinderknecht J, Dummer R, Kuhn FP, Yang KH, Lee L, Ayala RC, Racha J, Geng W, Moore D, Liu M, Joe AK, Bazan SP, Grippo JF. Pharmacol Res Perspect 3 e00113 (2015)
  284. Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma. Jain A, Tripathi R, Turpin CP, Wang C, Plattner R. Oncogene 36 4585-4596 (2017)
  285. Clinical outcome, role of BRAF(V600E), and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer? Nucera C, Pontecorvi A. Front Endocrinol (Lausanne) 3 33 (2012)
  286. Computational study on the unbinding pathways of B-RAF inhibitors and its implication for the difference of residence time: insight from random acceleration and steered molecular dynamics simulations. Niu Y, Li S, Pan D, Liu H, Yao X. Phys Chem Chem Phys 18 5622-5629 (2016)
  287. FOXD3 Regulates VISTA Expression in Melanoma. Rosenbaum SR, Knecht M, Mollaee M, Zhong Z, Erkes DA, McCue PA, Chervoneva I, Berger AC, Lo JA, Fisher DE, Gershenwald JE, Davies MA, Purwin TJ, Aplin AE. Cell Rep 30 510-524.e6 (2020)
  288. Functional characterization of a PROTAC directed against BRAF mutant V600E. Posternak G, Tang X, Maisonneuve P, Jin T, Lavoie H, Daou S, Orlicky S, Goullet de Rugy T, Caldwell L, Chan K, Aman A, Prakesch M, Poda G, Mader P, Wong C, Maier S, Kitaygorodsky J, Larsen B, Colwill K, Yin Z, Ceccarelli DF, Batey RA, Taipale M, Kurinov I, Uehling D, Wrana J, Durocher D, Gingras AC, Al-Awar R, Therrien M, Sicheri F. Nat Chem Biol 16 1170-1178 (2020)
  289. Comment Genetic-targeted therapy of thyroid cancer: a real promise. Xing M. Thyroid 19 805-809 (2009)
  290. Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors. Gopalsamy A, Ciszewski G, Hu Y, Lee F, Feldberg L, Frommer E, Kim S, Collins K, Wojciechowicz D, Mallon R. Bioorg Med Chem Lett 19 2735-2738 (2009)
  291. Phase I/II study of vemurafenib in patients with unresectable or recurrent melanoma with BRAF(V) (600) mutations. Yamazaki N, Kiyohara Y, Sugaya N, Uhara H. J Dermatol 42 661-666 (2015)
  292. Targeting non-canonical autophagy overcomes erlotinib resistance in tongue cancer. Huang K, Liu D. Tumour Biol 37 9625-9633 (2016)
  293. 19 F NMR-Based Fragment Screening for 14 Different Biologically Active RNAs and 10 DNA and Protein Counter-Screens. Binas O, de Jesus V, Landgraf T, Völklein AE, Martins J, Hymon D, Kaur Bains J, Berg H, Biedenbänder T, Fürtig B, Lakshmi Gande S, Niesteruk A, Oxenfarth A, Shahin Qureshi N, Schamber T, Schnieders R, Tröster A, Wacker A, Wirmer-Bartoschek J, Wirtz Martin MA, Stirnal E, Azzaoui K, Richter C, Sreeramulu S, José Blommers MJ, Schwalbe H. Chembiochem 22 423-433 (2021)
  294. Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors. Dietrich J, Gokhale V, Wang X, Hurley LH, Flynn GA. Bioorg Med Chem 18 292-304 (2010)
  295. Computational tools for the interactive exploration of proteomic and structural data. Morris JH, Meng EC, Ferrin TE. Mol Cell Proteomics 9 1703-1715 (2010)
  296. Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells. Eum KH, Ahn SK, Kang H, Lee M. Mol Cell Biochem 372 65-74 (2013)
  297. Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase. Patnaik S, Stevens KL, Gerding R, Deanda F, Shotwell JB, Tang J, Hamajima T, Nakamura H, Leesnitzer MA, Hassell AM, Shewchuck LM, Kumar R, Lei H, Chamberlain SD. Bioorg Med Chem Lett 19 3136-3140 (2009)
  298. Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma. Williams TE, Subramanian S, Verhagen J, McBride CM, Costales A, Sung L, Antonios-McCrea W, McKenna M, Louie AK, Ramurthy S, Levine B, Shafer CM, Machajewski T, Renhowe PA, Appleton BA, Amiri P, Chou J, Stuart D, Aardalen K, Poon D. ACS Med Chem Lett 6 961-965 (2015)
  299. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation. Kundu A, Quirit JG, Khouri MG, Firestone GL. Mol Carcinog 56 49-61 (2017)
  300. Mutation of the retinoblastoma tumor suppressor gene sensitizes cancers to mitotic inhibitor induced cell death. Zhao J, Zhang Z, Liao Y, Du W. Am J Cancer Res 4 42-52 (2014)
  301. Rapid, Microwave-Assisted Organic Synthesis of Selective (V600E)BRAF Inhibitors for Preclinical Cancer Research. Buck JR, Saleh S, Uddin MI, Manning HC. Tetrahedron Lett 53 4161-4165 (2012)
  302. Targeting Tyro3 ameliorates a model of PGRN-mutant FTLD-TDP via tau-mediated synaptic pathology. Fujita K, Chen X, Homma H, Tagawa K, Amano M, Saito A, Imoto S, Akatsu H, Hashizume Y, Kaibuchi K, Miyano S, Okazawa H. Nat Commun 9 433 (2018)
  303. The 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition. Yosaatmadja Y, Patterson AV, Smaill JB, Squire CJ. Acta Crystallogr D Biol Crystallogr 71 525-533 (2015)
  304. The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma. Giricz O, Mo Y, Dahlman KB, Cotto-Rios XM, Vardabasso C, Nguyen H, Matusow B, Bartenstein M, Polishchuk V, Johnson DB, Bhagat TD, Shellooe R, Burton E, Tsai J, Zhang C, Habets G, Greally JM, Yu Y, Kenny PA, Fields GB, Pradhan K, Stanley ER, Bernstein E, Bollag G, Gavathiotis E, West BL, Sosman JA, Verma AK. JCI Insight 3 (2018)
  305. BRAF-mutated cells activate GCN2-mediated integrated stress response as a cytoprotective mechanism in response to vemurafenib. Nagasawa I, Kunimasa K, Tsukahara S, Tomida A. Biochem Biophys Res Commun 482 1491-1497 (2017)
  306. Dinuclear and heptanuclear complexes of copper(II) with 7-azaindole ligand: synthesis, characterization, magnetic properties, and biological activity. Przyojski JA, Myers NN, Arman HD, Prosvirin A, Dunbar KR, Natarajan M, Krishnan M, Mohan S, Walmsley JA. J Inorg Biochem 127 175-181 (2013)
  307. Discovery of highly potent and selective type I B-Raf kinase inhibitors. Wang X, Berger DM, Salaski EJ, Torres N, Hu Y, Levin JI, Powell D, Wojciechowicz D, Collins K, Frommer E. Bioorg Med Chem Lett 19 6571-6574 (2009)
  308. News Effectively targeting BRAF in melanoma: a formidable challenge. Fecher LA, Amaravadi R, Schuchter LM. Pigment Cell Melanoma Res 21 410-411 (2008)
  309. Functional profiling of live melanoma samples using a novel automated platform. Schayowitz A, Bertenshaw G, Jeffries E, Schatz T, Cotton J, Villanueva J, Herlyn M, Krepler C, Vultur A, Xu W, Yu GH, Schuchter L, Clark DP. PLoS One 7 e52760 (2012)
  310. Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening. La J, Latham CF, Tinetti RN, Johnson A, Tyssen D, Huber KD, Sluis-Cremer N, Simpson JS, Headey SJ, Chalmers DK, Tachedjian G. Proc Natl Acad Sci U S A 112 6979-6984 (2015)
  311. Inferring primary tumor sites from mutation spectra: a meta-analysis of histology-specific aberrations in cancer-derived cell lines. Dietlein F, Eschner W. Hum Mol Genet 23 1527-1537 (2014)
  312. Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines. Noguchi K, Dalton AC, Howley BV, McCall BJ, Yoshida A, Diehl JA, Howe PH. PLoS One 12 e0177830 (2017)
  313. KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations. Liu X, Zhang SM, McGeary MK, Krykbaeva I, Lai L, Jansen DJ, Kales SC, Simeonov A, Hall MD, Kelly DP, Bosenberg MW, Yan Q. Mol Cancer Ther 18 706-717 (2019)
  314. MITF depletion elevates expression levels of ERBB3 receptor and its cognate ligand NRG1-beta in melanoma. Alver TN, Lavelle TJ, Longva AS, Øy GF, Hovig E, Bøe SL. Oncotarget 7 55128-55140 (2016)
  315. Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation. Virzì AR, Gentile A, Benvenuti S, Comoglio PM. Proc Natl Acad Sci U S A 115 10058-10063 (2018)
  316. The phosphorylation specificity of B-RAF WT, B-RAF D594V, B-RAF V600E and B-RAF K601E kinases: an in silico study. Fratev F, Jónsdóttir SO. J Mol Graph Model 28 598-603 (2010)
  317. The role of autophagy in cytotoxicity induced by new oncogenic B-Raf inhibitor UI-152 in v-Ha-ras transformed fibroblasts. Ahn JH, Ahn SK, Lee M. Biochem Biophys Res Commun 417 857-863 (2012)
  318. A novel approach for the detection and genetic analysis of live melanoma circulating tumor cells. Xu MJ, Cooke M, Steinmetz D, Karakousis G, Saxena D, Bartlett E, Xu X, Hahn SM, Dorsey JF, Kao GD. PLoS One 10 e0123376 (2015)
  319. An in silico study of the molecular basis of B-RAF activation and conformational stability. Fratev FF, Jónsdóttir SO. BMC Struct Biol 9 47 (2009)
  320. Challenges in the delivery of therapies to melanoma brain metastases. Gampa G, Vaidhyanathan S, Resman BW, Parrish KE, Markovic SN, Sarkaria JN, Elmquist WF. Curr Pharmacol Rep 2 309-325 (2016)
  321. Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E Conformation. Grasso M, Estrada MA, Ventocilla C, Samanta M, Maksimoska J, Villanueva J, Winkler JD, Marmorstein R. ACS Chem Biol 11 2876-2888 (2016)
  322. Design and Development of Fluorescent Vemurafenib Analogs for In Vivo Imaging. Mikula H, Stapleton S, Kohler RH, Vinegoni C, Weissleder R. Theranostics 7 1257-1265 (2017)
  323. Enhanced cytotoxicity of reovirus and radiotherapy in melanoma cells is mediated through increased viral replication and mitochondrial apoptotic signalling. McEntee G, Kyula JN, Mansfield D, Smith H, Wilkinson M, Gregory C, Roulstone V, Coffey M, Harrington KJ. Oncotarget 7 48517-48532 (2016)
  324. Exploring a cascade Heck-Suzuki reaction based route to kinase inhibitors using design of experiments. Ekebergh A, Lingblom C, Sandin P, Wennerås C, Mårtensson J. Org Biomol Chem 13 3382-3392 (2015)
  325. Fragment library design: efficiently hunting drugs in chemical space. Drug Discov Today Technol 7 e147-202 (2010)
  326. Ku80 promotes melanoma growth and regulates antitumor effect of melatonin by targeting HIF1-α dependent PDK-1 signaling pathway. Liu T, Jin L, Chen M, Zheng Z, Lu W, Fan W, Li L, Zheng F, Zhu Q, Qiu H, Liu J, Chen M, Tian C, Hu Z, Zhang C, Luo M, Li J, Kang T, Yang L, Li Y, Deng W. Redox Biol 25 101197 (2019)
  327. Parsing out the complexity of RAF inhibitor resistance. McMahon M. Pigment Cell Melanoma Res 24 361-365 (2011)
  328. RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors. Lei FX, Jin L, Liu XY, Lai F, Yan XG, Farrelly M, Guo ST, Zhao XH, Zhang XD. Cell Death Dis 9 679 (2018)
  329. Structure-based de novo design and biochemical evaluation of novel BRAF kinase inhibitors. Park H, Jeong Y, Hong S. Bioorg Med Chem Lett 22 1027-1030 (2012)
  330. Therapeutic options in cutaneous melanoma: latest developments. Amaria RN, Lewis KD, Gonzalez R. Ther Adv Med Oncol 3 245-251 (2011)
  331. A large-scale RNAi screen identifies LCMR1 as a critical regulator of Tspan8-mediated melanoma invasion. Agaësse G, Barbollat-Boutrand L, Sulpice E, Bhajun R, El Kharbili M, Berthier-Vergnes O, Degoul F, de la Fouchardière A, Berger E, Voeltzel T, Lamartine J, Gidrol X, Masse I. Oncogene 36 446-457 (2017)
  332. Cell cycle-tailored targeting of metastatic melanoma: Challenges and opportunities. Haass NK, Gabrielli B. Exp Dermatol 26 649-655 (2017)
  333. Discovery, characterization, and lead optimization of 7-azaindole non-nucleoside HIV-1 reverse transcriptase inhibitors. Stanton RA, Lu X, Detorio M, Montero C, Hammond ET, Ehteshami M, Domaoal RA, Nettles JH, Feraud M, Schinazi RF. Bioorg Med Chem Lett 26 4101-4105 (2016)
  334. Drug nanocarriers for cancer chemotherapy based on microemulsions: The case of Vemurafenib analog PLX4720. Theochari I, Goulielmaki M, Danino D, Papadimitriou V, Pintzas A, Xenakis A. Colloids Surf B Biointerfaces 154 350-356 (2017)
  335. Drug targets and predictive biomarkers in the management of metastatic melanoma. Thumar J, Giesen E, Kluger HM. Pharmgenomics Pers Med 5 139-148 (2012)
  336. Energetics and structural characterization of the "DFG-flip" conformational transition of B-RAF kinase: a SITS molecular dynamics study. Shao Q, Xu Z, Wang J, Shi J, Zhu W. Phys Chem Chem Phys 19 1257-1267 (2017)
  337. FGFR1 Kinase Inhibitors: Close Regioisomers Adopt Divergent Binding Modes and Display Distinct Biophysical Signatures. Klein T, Tucker J, Holdgate GA, Norman RA, Breeze AL. ACS Med Chem Lett 5 166-171 (2014)
  338. Long glucocorticoid-induced leucine zipper regulates human thyroid cancer cell proliferation. Ayroldi E, Petrillo MG, Marchetti MC, Cannarile L, Ronchetti S, Ricci E, Cari L, Avenia N, Moretti S, Puxeddu E, Riccardi C. Cell Death Dis 9 305 (2018)
  339. Optimization of personalized therapies for anticancer treatment. Vazquez A. BMC Syst Biol 7 31 (2013)
  340. News Stopping a chromatin enzyme. Simon JA. Nat Chem Biol 8 875-876 (2012)
  341. Structure-based design of low-nanomolar PIM kinase inhibitors. Ishchenko A, Zhang L, Le Brazidec JY, Fan J, Chong JH, Hingway A, Raditsis A, Singh L, Elenbaas B, Hong VS, Marcotte D, Silvian L, Enyedy I, Chao J. Bioorg Med Chem Lett 25 474-480 (2015)
  342. The siRNA-mediated downregulation of N-Ras sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors. Ahn JH, Lee M. Mol Cell Biochem 392 239-247 (2014)
  343. Letter The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors. Kaplan FM, Mastrangelo MJ, Aplin AE. J Invest Dermatol 130 2669-2671 (2010)
  344. miR‑590‑5p inhibits tumor growth in malignant melanoma by suppressing YAP1 expression. Mou K, Ding M, Han D, Zhou Y, Mu X, Liu W, Wang L. Oncol Rep 40 2056-2066 (2018)
  345. Aberrant expression of COT is related to recurrence of papillary thyroid cancer. Lee J, Jeong S, Park JH, Lee CR, Ku CR, Kang SW, Jeong JJ, Nam KH, Shin DY, Lee EJ, Chung WY, Jo YS. Medicine (Baltimore) 94 e548 (2015)
  346. Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression. Michaelis M, Rothweiler F, Nerreter T, van Rikxoort M, Zehner R, Dirks WG, Wiese M, Cinatl J. BMC Res Notes 7 710 (2014)
  347. Binding mode information improves fragment docking. Jacquemard C, Drwal MN, Desaphy J, Kellenberger E. J Cheminform 11 24 (2019)
  348. Combining pharmacophore, docking and substructure search approaches to identify and optimize novel B-RafV600E inhibitors. Xu Z, Yan G, Wang G, Li B, Zhu J, Sun P, Zhang X, Luo C, Wang H, Zhu W. Bioorg Med Chem Lett 22 5428-5437 (2012)
  349. Conjunctival Melanoma Targeted Therapy: MAPK and PI3K/mTOR Pathways Inhibition. El Zaoui I, Bucher M, Rimoldi D, Nicolas M, Kaya G, Pescini Gobert R, Bedoni N, Schalenbourg A, Sakina E, Zografos L, Leyvraz S, Riggi N, Rivolta C, Moulin AP. Invest Ophthalmol Vis Sci 60 2764-2772 (2019)
  350. Cytotoxic Effect of Vanicosides A and B from Reynoutria sachalinensis Against Melanotic and Amelanotic Melanoma Cell Lines and in silico Evaluation for Inhibition of BRAFV600E and MEK1. Nawrot-Hadzik I, Choromańska A, Abel R, Preissner R, Saczko J, Matkowski A, Hadzik J. Int J Mol Sci 21 (2020)
  351. Design, synthesis and preliminary biological evaluation of C-8 substituted guanine derivatives as small molecular inhibitors of FGFRs. Ye F, Chen L, Hu L, Xiao T, Yu S, Chen D, Wang Y, Liang G, Liu Z, Wang S. Bioorg Med Chem Lett 25 1556-1560 (2015)
  352. Discovery and Characterization of a Biologically Active Non-ATP-Competitive p38 MAP Kinase Inhibitor. Wilson BA, Alam MS, Guszczynski T, Jakob M, Shenoy SR, Mitchell CA, Goncharova EI, Evans JR, Wipf P, Liu G, Ashwell JD, O'Keefe BR. J Biomol Screen 21 277-289 (2016)
  353. Genomic and signalling pathway characterization of the NZM panel of melanoma cell lines: A valuable model for studying the impact of genetic diversity in melanoma. Tran KB, Gimenez G, Tsai P, Kolekar S, Rodger EJ, Chatterjee A, Jabed A, Shih JH, Joseph WR, Marshall ES, Wang Q, Print CG, Eccles MR, Baguley BC, Shepherd PR. Pigment Cell Melanoma Res 34 136-143 (2021)
  354. Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma. Tang HC, Chen YC. Int J Nanomedicine 10 3131-3146 (2015)
  355. Natural Killer cell control of BRAFV600E mutant melanoma during targeted therapy. de Andrade LF, Ngiow SF, Martinet L, Smyth MJ. Oncoimmunology 4 e998119 (2015)
  356. Nucleotide-Free sB-Raf is Preferentially Bound by Hsp90 and Cdc37 In Vitro. Eckl JM, Daake M, Schwartz S, Richter K. J Mol Biol 428 4185-4196 (2016)
  357. The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors. Coperchini F, Croce L, Croce L, Denegri M, Awwad O, Ngnitejeu ST, Muzza M, Capelli V, Latrofa F, Persani L, Chiovato L, Rotondi M. Sci Rep 9 4390 (2019)
  358. The genesis of Zelboraf: targeting mutant B-Raf in melanoma. Davis MJ, Schlessinger J. J Cell Biol 199 15-19 (2012)
  359. Vemurafenib Inhibits Active PTK6 in PTEN-null Prostate Tumor Cells. Wozniak DJ, Hitchinson B, Gilic MB, Bie W, Gaponenko V, Tyner AL. Mol Cancer Ther 18 937-946 (2019)
  360. B-Raf mutation and papillary thyroid carcinoma patients. Jiang L, Chu H, Zheng H. Oncol Lett 11 2699-2705 (2016)
  361. Cumingianoside A, a Phyto-Triterpenoid Saponin Inhibits Acquired BRAF Inhibitor Resistant Melanoma Growth via Programmed Cell Death. Cvetanova B, Shen YC, Shyur LF. Front Pharmacol 10 30 (2019)
  362. DPS-2: A Novel Dual MEK/ERK and PI3K/AKT Pathway Inhibitor with Powerful Ex Vivo and In Vivo Anticancer Properties. Goulielmaki M, Assimomytis N, Rozanc J, Taki E, Christodoulou I, Alexopoulos LG, Zoumpourlis V, Pintzas A, Papahatjis D. Transl Oncol 12 932-950 (2019)
  363. Design, synthesis, and identification of a novel napthalamide-isoselenocyanate compound NISC-6 as a dual Topoisomerase-IIα and Akt pathway inhibitor, and evaluation of its anti-melanoma activity. Karelia DN, Sk UH, Singh P, Gowda ASP, Pandey MK, Ramisetti SR, Amin S, Sharma AK. Eur J Med Chem 135 282-295 (2017)
  364. Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells. You KS, Yi YW, Cho J, Seong YS. Cancers (Basel) 13 (2021)
  365. Energy parasites trigger oncogene mutation. Pokorný J, Pokorný J, Jandová A, Kobilková J, Vrba J, Vrba J. Int J Radiat Biol 92 577-582 (2016)
  366. Eruptive squamous cell carcinomas after vemurafenib therapy. Mays R, Curry J, Kim K, Tsai K, Arora A, Khan F, Ramirez-Fort M, Ciurea A. J Cutan Med Surg 17 419-422 (2013)
  367. Expanding medicinal chemistry into 3D space: metallofragments as 3D scaffolds for fragment-based drug discovery. Morrison CN, Prosser KE, Stokes RW, Cordes A, Metzler-Nolte N, Cohen SM. Chem Sci 11 1216-1225 (2019)
  368. Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode. Fujimoto J, Kurasawa O, Takagi T, Liu X, Banno H, Kojima T, Asano Y, Nakamura A, Nambu T, Hata A, Ishii T, Sameshima T, Debori Y, Miyamoto M, Klein MG, Tjhen R, Sang BC, Levin I, Lane SW, Snell GP, Li K, Kefala G, Hoffman ID, Ding SC, Cary DR, Mizojiri R. ACS Med Chem Lett 10 1498-1503 (2019)
  369. Immunologic effects of an orally available BRAFV600E inhibitor in BRAF wild-type murine models. Vosganian GS, Bos R, Sherman LA. J Immunother 35 473-477 (2012)
  370. Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis. Zarnegar S, Durham BH, Khattar P, Shukla NN, Benayed R, Lacouture ME, Lavi E, Lyden DC, Diamond EL, Dunkel IJ, Abdel-Wahab O. Pediatr Blood Cancer 65 (2018)
  371. Pragmatic medicine in solid cancer: a translational alternative to precision medicine. Brábek J, Rosel D, Fernandes M. Onco Targets Ther 9 1839-1855 (2016)
  372. Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold. Suebsuwong C, Dai B, Pinkas DM, Duddupudi AL, Li L, Bufton JC, Schlicher L, Gyrd-Hansen M, Hu M, Bullock AN, Degterev A, Cuny GD. Eur J Med Chem 200 112417 (2020)
  373. Rigidification Dramatically Improves Inhibitor Selectivity for RAF Kinases. Assadieskandar A, Yu C, Maisonneuve P, Kurinov I, Sicheri F, Zhang C. ACS Med Chem Lett 10 1074-1080 (2019)
  374. Systemic therapy of non-resectable metastatic melanoma. Orouji A, Goerdt S, Utikal J. Cancers (Basel) 2 955-969 (2010)
  375. The discovery of potent and selective 4-aminothienopyridines as B-Raf kinase inhibitors. Tang J, Lackey KE, Dickerson SH. Bioorg Med Chem Lett 23 66-70 (2013)
  376. An NKX2-1/ERK/WNT feedback loop modulates gastric identity and response to targeted therapy in lung adenocarcinoma. Zewdu R, Mehrabad EM, Ingram K, Fang P, Gillis KL, Camolotto SA, Orstad G, Jones A, Mendoza MC, Spike BT, Snyder EL. Elife 10 (2021)
  377. CaDrA: A Computational Framework for Performing Candidate Driver Analyses Using Genomic Features. Kartha VK, Sebastiani P, Kern JG, Zhang L, Varelas X, Monti S. Front Genet 10 121 (2019)
  378. Carnosic acid, an inducer of NAD(P)H quinone oxidoreductase 1, enhances the cytotoxicity of β-lapachone in melanoma cell lines. Arakawa N, Okubo A, Yasuhira S, Takahashi K, Amano H, Akasaka T, Masuda T, Shibazaki M, Maesawa C. Oncol Lett 15 2393-2400 (2018)
  379. Combination therapy targeting the elevated interleukin-6 level reduces invasive migration of BRAF inhibitor-resistant melanoma cells. Mohapatra P, Prasad CP, Andersson T. Mol Oncol 13 480-494 (2019)
  380. Combined Protein- and Ligand-Observed NMR Workflow to Screen Fragment Cocktails against Multiple Proteins: A Case Study Using Bromodomains. Johnson JA, Olson NM, Tooker MJ, Bur SK, Pomerantz WCK. Molecules 25 (2020)
  381. Discovery of EBI-907: A highly potent and orally active B-Raf(V600E) inhibitor for the treatment of melanoma and associated cancers. Lu B, Cao H, Cao J, Huang S, Hu Q, Liu D, Shen R, Shen X, Tao W, Wan H, Wang D, Yan Y, Yang L, Zhang J, Zhang L, Zhang L, Zhang M. Bioorg Med Chem Lett 26 819-823 (2016)
  382. Disease Variants of FGFR3 Reveal Molecular Basis for the Recognition and Additional Roles for Cdc37 in Hsp90 Chaperone System. Bunney TD, Inglis AJ, Sanfelice D, Farrell B, Kerr CJ, Thompson GS, Masson GR, Thiyagarajan N, Svergun DI, Williams RL, Breeze AL, Katan M. Structure 26 446-458.e8 (2018)
  383. Electrostatic mechanism of V600E mutation-induced B-Raf constitutive activation in colorectal cancer: molecular implications for the selectivity difference between type-I and type-II inhibitors. Liu T, Wang Z, Guo P, Ding N. Eur Biophys J 48 73-82 (2019)
  384. Good clinical and radiological response to BRAF inhibitor in patient with metastatic thin melanoma. Quintyne KI, Baker S, Wallis F, Gupta R. BMJ Case Rep 2012 (2012)
  385. Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-Raf(V600E) kinase. Wenglowsky S, Ren L, Grina J, Hansen JD, Laird ER, Moreno D, Dinkel V, Gloor SL, Hastings G, Rana S, Rasor K, Sturgis HL, Voegtli WC, Vigers G, Willis B, Mathieu S, Rudolph J. Bioorg Med Chem Lett 24 1923-1927 (2014)
  386. How Size Matters: Diversity for Fragment Library Design. Shi Y, von Itzstein M. Molecules 24 (2019)
  387. Identification and Characterization of Small-Molecule Inhibitors to Selectively Target the DFG-in over the DFG-out Conformation of the B-Raf Kinase V600E Mutant in Colorectal Cancer. Yao H, Sun Q, Zhu J. Arch Pharm (Weinheim) 349 808-815 (2016)
  388. Identification and synthesis of N-(thiophen-2-yl) benzamide derivatives as BRAF(V600E) inhibitors. Xie Y, Chen X, Qin J, Kong X, Ye F, Jiang Y, Liu H, Jiang H, Marmorstein R, Luo C. Bioorg Med Chem Lett 23 2306-2312 (2013)
  389. Identification of a Novel Quinoxaline-Isoselenourea Targeting the STAT3 Pathway as a Potential Melanoma Therapeutic. Alcolea V, Karelia DN, Pandey MK, Plano D, Singh P, Palop JA, Amin S, Sanmartín C, Sharma AK. Int J Mol Sci 20 (2019)
  390. Inhibition of Patched Drug Efflux Increases Vemurafenib Effectiveness against Resistant BrafV600E Melanoma. Signetti L, Elizarov N, Simsir M, Paquet A, Douguet D, Labbal F, Debayle D, Di Giorgio A, Biou V, Girard C, Duca M, Bretillon L, Bertolotto C, Verrier B, Azoulay S, Mus-Veteau I. Cancers (Basel) 12 (2020)
  391. Interleukin-like EMT inducer (ILEI) promotes melanoma invasiveness and is transcriptionally up-regulated by upstream stimulatory factor-1 (USF-1). Noguchi K, Dincman TA, Dalton AC, Howley BV, McCall BJ, Mohanty BK, Howe PH. J Biol Chem 293 11401-11414 (2018)
  392. Key drivers of biomedical innovation in cancer drug discovery. Huber MA, Kraut N. EMBO Mol Med 7 12-16 (2015)
  393. Multiobjective optimization identifies cancer-selective combination therapies. Pulkkinen OI, Gautam P, Mustonen V, Aittokallio T. PLoS Comput Biol 16 e1008538 (2020)
  394. NMR quality control of fragment libraries for screening. Sreeramulu S, Richter C, Kuehn T, Azzaoui K, Blommers MJJ, Del Conte R, Fragai M, Trieloff N, Schmieder P, Nazaré M, Specker E, Ivanov V, Oschkinat H, Banci L, Schwalbe H. J Biomol NMR 74 555-563 (2020)
  395. Optimization of diarylthiazole B-raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low paradoxical effect. Pulici M, Traquandi G, Marchionni C, Modugno M, Lupi R, Amboldi N, Casale E, Colombo N, Corti L, Fasolini M, Gasparri F, Pastori W, Scolaro A, Donati D, Felder E, Galvani A, Isacchi A, Pesenti E, Ciomei M. ChemMedChem 10 276-295 (2015)
  396. Comment Pros and cons of cellular studies in developing new drugs for thyroid cancers. Salvatore G, Carlomagno F, Santoro M. Thyroid 18 819-822 (2008)
  397. Rescue of cell cycle progression in BRAFV600E inhibitor-resistant human melanoma by a chromatin modifier. Toress-Collado AX, Nazarian R, Jazirehi AR. Tumour Biol 39 1010428317721620 (2017)
  398. Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. Whiteaker JR, Sharma K, Hoffman MA, Kuhn E, Zhao L, Cocco AR, Schoenherr RM, Kennedy JJ, Voytovich U, Lin C, Fang B, Bowers K, Whiteley G, Colantonio S, Bocik W, Roberts R, Hiltke T, Boja E, Rodriguez H, McCormick F, Holderfield M, Carr SA, Koomen JM, Paulovich AG. Cell Rep Methods 1 100015 (2021)
  399. The role of polo-like kinase 3 in the response of BRAF-mutant cells to targeted anticancer therapies. Babagana M, Kichina JV, Slabodkin H, Johnson S, Maslov A, Brown L, Attwood K, Nikiforov MA, Kandel ES. Mol Carcinog 59 5-14 (2020)
  400. A B-Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies. Yao K, Zhou E, Cheng C. Cancer Med 11 1232-1243 (2022)
  401. A Fragment-Based Approach for the Development of G-Quadruplex Ligands: Role of the Amidoxime Moiety. Tassinari M, Lena A, Butovskaya E, Pirota V, Nadai M, Freccero M, Doria F, Richter SN. Molecules 23 (2018)
  402. A Raf kinase inhibitor demonstrates antiviral activities both in vitro and in vivo against different genotypes of virulent Newcastle disease virus. Yin R, Liu X, Zhang P, Chen Y, Xie G, Ai L, Xue C, Qian J, Bi Y, Chen J, Sun Y, Stoeger T, Ding Z. Antiviral Res 133 140-144 (2016)
  403. A combined 3D-QSAR and molecular docking strategy to understand the binding mechanism of (V600E)B-RAF inhibitors. Ul-Haq Z, Mahmood U, Reza S. Mol Divers 16 771-785 (2012)
  404. Alkyne Activation in the Diversity Oriented Synthesis of sp2 -Rich Scaffolds: A Biased Library Approach for Targeting Polynucleotides (DNA/RNA). Chen S, Priebbenow DL, Somkhit J, Scullino CV, Agama K, Pommier Y, Flynn BL. Chemistry 28 e202201925 (2022)
  405. BRAF inhibition sensitizes melanoma cells to α-amanitin via decreased RNA polymerase II assembly. Frischknecht L, Britschgi C, Galliker P, Christinat Y, Vichalkovski A, Gstaiger M, Kovacs WJ, Krek W. Sci Rep 9 7779 (2019)
  406. CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma. Li Z, Wang B, Gu S, Jiang P, Sahu A, Chen CH, Han T, Shi S, Wang X, Traugh N, Liu H, Liu Y, Wu Q, Brown M, Xiao T, Boland GM, Shirley Liu X. Genomics Proteomics Bioinformatics 18 26-40 (2020)
  407. Colorectal Cancer Patient-Derived 2D and 3D Models Efficiently Recapitulate Inter- and Intratumoral Heterogeneity. Zhao Y, Zhang B, Ma Y, Zhao F, Chen J, Wang B, Jin H, Zhou F, Guan J, Zhao Q, Wang H, Liu Q, Zhao F, Wang X. Adv Sci (Weinh) 9 e2201539 (2022)
  408. Converting biology into clinical benefit: lessons learned from BRAF inhibitors. McQuade J, Davies MA. Melanoma Manag 2 241-254 (2015)
  409. Cutaneous side effects of vemurafenib: a case report and discussion. Shea SM, Boyd K, Patterson J. Wien Med Wochenschr 163 376-379 (2013)
  410. DFT-based reactivity and combined QSAR, molecular docking of 1,2,4,5-Tetrazine derivatives as inhibitors of Pim-1 kinase. Hazhazi H, Melkemi N, Salah T, Bouachrine M. Heliyon 5 e02451 (2019)
  411. Dabrafenib for the treatment of melanoma. Amaria RN, Kim KB. Expert Opin Pharmacother 15 1043-1050 (2014)
  412. Design and Synthesis of Hsp90 Inhibitors with B-Raf and PDHK1 Multi-Target Activity. Pinzi L, Foschi F, Christodoulou MS, Passarella D, Rastelli G. ChemistryOpen 10 1177-1185 (2021)
  413. Developing a Kinase-Specific Target Selection Method Using a Structure-Based Machine Learning Approach. Afanasyeva A, Nagao C, Mizuguchi K. Adv Appl Bioinform Chem 13 27-40 (2020)
  414. Development of Highly Sensitive Biosensors of RAF Dimerization in Cells. Miyamoto K, Sawa M. Sci Rep 9 636 (2019)
  415. Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-RafV600E inhibitors. Wang GM, Wang X, Zhu JM, Guo BB, Yang Z, Xu ZJ, Li B, Wang HY, Meng LH, Zhu WL, Ding J. Acta Pharmacol Sin 38 1059-1068 (2017)
  416. Drugmonizome and Drugmonizome-ML: integration and abstraction of small molecule attributes for drug enrichment analysis and machine learning. Kropiwnicki E, Evangelista JE, Stein DJ, Clarke DJB, Lachmann A, Kuleshov MV, Jeon M, Jagodnik KM, Ma'ayan A. Database (Oxford) 2021 (2021)
  417. EGFR inhibition enhances the antitumor efficacy of a selective BRAF V600E inhibitor in thyroid cancer cell lines. Jia Y, Zhang C, Hu C, Yu Y, Zheng X, Li Y, Gao M. Oncol Lett 15 6763-6769 (2018)
  418. Fate and plasticity of the epidermis in response to congenital activation of BRAF. Krishnaswami SR, Kumar S, Ordoukhanian P, Yu BD. J Invest Dermatol 135 481-489 (2015)
  419. Congress Highlights from the perspectives in melanoma XII conference. Kirkwood JM, Eggermont A. Pigment Cell Melanoma Res 22 156-165 (2009)
  420. Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma. Schuiveling M, Tonk EHJ, Verheijden RJ, Suijkerbuijk KPM. Cancer Immunol Immunother 70 1491-1496 (2021)
  421. Identification and Characterization of a B-Raf Kinase α-Helix Critical for the Activity of MEK Kinase in MAPK Signaling. Nguyen D, Lin LY, Zhou JO, Kibby E, Sia TW, Tillis TD, Vapuryan N, Xu MR, Potluri R, Shin Y, Erler EA, Bronkema N, Boehlmer DJ, Chung CD, Burkhard C, Zeng SH, Grasso M, Acevedo LA, Marmorstein R, Fera D. Biochemistry 59 4755-4765 (2020)
  422. In Vivo ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma. Sanchez IM, Purwin TJ, Chervoneva I, Erkes DA, Nguyen MQ, Davies MA, Nathanson KL, Kemper K, Peeper DS, Aplin AE. Mol Cancer Ther 18 1637-1648 (2019)
  423. Melanocytes and melanoma: hooked on elongation. Lister JA. Pigment Cell Melanoma Res 24 397-398 (2011)
  424. Oil-In-Water Microemulsions as Hosts for Benzothiophene-Based Cytotoxic Compounds: An Effective Combination. Theochari I, Papadimitriou V, Papahatjis D, Assimomytis N, Pappou E, Pratsinis H, Xenakis A, Pletsa V. Biomimetics (Basel) 3 (2018)
  425. RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics. Bekele RT, Samant AS, Nassar AH, So J, Garcia EP, Curran CR, Hwang JH, Mayhew DL, Nag A, Thorner AR, Börcsök J, Sztupinszki Z, Pan CX, Bellmunt J, Kwiatkowski DJ, Sonpavde GP, Van Allen EM, Mouw KW. J Clin Invest 131 e147849 (2021)
  426. ROS-mediated SRMS activation confers platinum resistance in ovarian cancer. Jiang Y, Song L, Lin Y, Nowialis P, Gao Q, Li T, Li B, Mao X, Song Q, Xing C, Zheng G, Huang S, Jin L. Oncogene 42 1672-1684 (2023)
  427. Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy. Lacouture ME, Wainberg ZA, Patel AB, Anadkat MJ, Stemmer SM, Shacham-Shmueli E, Medina E, Zelinger G, Shelach N, Ribas A. Cancer Discov 11 2158-2167 (2021)
  428. Role of serine 365 in BRAF V600E sensitivity to RAF inhibition. Vido MJ, Rock J, Aplin AE. Pigment Cell Melanoma Res 34 696-702 (2021)
  429. Saturation mutagenesis of a predicted ancestral Syk-family kinase. Hobbs HT, Shah NH, Shoemaker SR, Amacher JF, Marqusee S, Kuriyan J. Protein Sci 31 e4411 (2022)
  430. Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib. Tkacik E, Li K, Gonzalez-Del Pino G, Ha BH, Vinals J, Park E, Beyett TS, Eck MJ. J Biol Chem 299 104634 (2023)
  431. Editorial Targeted treatment for melanoma. Monga M, Abraham J. Expert Rev Anticancer Ther 12 1113-1115 (2012)
  432. Comment Targeting B-Raf as a treatment strategy for polycystic kidney disease. Sas KM. Am J Physiol Renal Physiol 299 F942-3 (2010)
  433. Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma. Glasheen MQ, Caksa S, Young AG, Wilski NA, Ott CA, Chervoneva I, Flaherty KT, Herlyn M, Xu X, Aplin AE, Capparelli C. Mol Cancer Ther 22 1087-1099 (2023)
  434. 19F multiple-quantum coherence NMR spectroscopy for probing protein-ligand interactions. Zawadzka-Kazimierczuk A, Somlyay M, Kaehlig H, Iakobson G, Beier P, Konrat R. RSC Adv 8 40687-40692 (2018)
  435. A Novel Acetylation-Immune Subtyping for the Identification of a BET Inhibitor-Sensitive Subgroup in Melanoma. Wang L, Zhang L, Li S, Cao L, Li K, Zhao W. Pharmaceuticals (Basel) 16 1037 (2023)
  436. A chondroitin sulfate proteoglycan 4‑specific monoclonal antibody inhibits melanoma cell invasion in a spheroid model. Uranowska K, Samadaei M, Kalic T, Pinter M, Breiteneder H, Hafner C. Int J Oncol 59 (2021)
  437. A competitive co-cultivation assay for cancer drug specificity evaluation. El Debs BW, Tschulena U, Griffiths AD, Merten CA. J Biomol Screen 16 818-824 (2011)
  438. A novel phosphorylation site involved in dissociating RAF kinase from the scaffolding protein 14-3-3 and disrupting RAF dimerization. Yu A, Nguyen DH, Nguyen TJ, Wang Z. J Biol Chem 299 105188 (2023)
  439. A plate-based assay to measure cellular ERK substrate phosphorylation: utility for drug discovery of the MAPK-signaling cascade. Ramaswamy S, Yen I, Sideris S, Malek S, Heise CE. Assay Drug Dev Technol 8 497-503 (2010)
  440. Acquired and intrinsic resistance to vemurafenib in BRAFV600E -driven melanoma brain metastases. Zhang P, Kuil LE, Buil LCM, Freriks S, Beijnen JH, van Tellingen O, de Gooijer MC. FEBS Open Bio 14 96-111 (2024)
  441. Activity and Selectivity of Novel Chemical Metallic Complexes with Potential Anticancer Effects on Melanoma Cells. Ciardulli MC, Mariconda A, Sirignano M, Lamparelli EP, Longo R, Scala P, D'Auria R, Santoro A, Guadagno L, Della Porta G, Longo P. Molecules 28 4851 (2023)
  442. An Integrative Gene Expression and Mathematical Flux Balance Analysis Identifies Targetable Redox Vulnerabilities in Melanoma Cells. Paudel BB, Lewis JE, Hardeman KN, Hayford CE, Robbins CJ, Stauffer PE, Codreanu SG, Sherrod SD, McLean JA, Kemp ML, Quaranta V. Cancer Res 80 4565-4577 (2020)
  443. Anti-tumor activity of the pan-RAF inhibitor TAK-580 in combination with KPT-330 (selinexor) in multiple myeloma. Suzuki R, Kitamura Y, Ogiya D, Ogawa Y, Kawada H, Ando K. Int J Hematol 115 233-243 (2022)
  444. BRAFV600E mutation in papillary thyroid carcinoma: a potential target for therapy? Soares P, Preto A, Sobrinho-Simões M. Expert Rev Endocrinol Metab 4 467-480 (2009)
  445. Co-Treatment of Chloroquine and Trametinib Inhibits Melanoma Cell Proliferation and Decreases Immune Cell Infiltration. Degan S, May BL, Jin YJ, Hammoda MB, Sun H, Zhang G, Wang Y, Erdmann D, Warren W, Zhang JY. Front Oncol 12 782877 (2022)
  446. Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study. Pópulo H, Domingues B, Sampaio C, Lopes JM, Soares P. J Exp Pharmacol 13 521-535 (2021)
  447. Concordance and Discordance Rates of V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)V600E Status in Metastatic against Primary Lesion of Melanoma: A Meta-analysis. Yokomichi H, Inozume T, Wada M, Asai J, Igaki H, Namikawa K, Hayashi A, Fukushima S, Fujimura T, Koga H, Nakamura Y, Mochizuki M, Yamagata Z. JMA J 3 274-279 (2020)
  448. Design, synthesis and biological evaluation of 1H-pyrrolo[2,3-b]pyridine derivatives as potent fibroblast growth factor receptor inhibitors. Su X, Liu Z, Yue L, Wu X, Wei W, Que H, Ye T, Luo Y, Zhang Y. RSC Adv 11 20651-20661 (2021)
  449. Determination of a novel B-Raf(V600E) and EGFR dual inhibitor in rat plasma by HPLC-MS/MS and its application in a pharmacokinetic study. Zhou ZL, Deng JF, Li YJ, Chang Y, Cheng HM. J Pharm Biomed Anal 129 142-147 (2016)
  450. Differential Sensitivity of Wild-Type and BRAF-Mutated Cells to Combined BRAF and Autophagy Inhibition. Yeom H, Hwang SH, Han BI, Lee M. Biomol Ther (Seoul) 29 434-444 (2021)
  451. Discovery of novel elongator protein 2 inhibitors by compound library screening using surface plasmon resonance. Xu CP, Qi Y, Cui Z, Yang YJ, Wang J, Hu YJ, Yu B, Wang FZ, Yang QP, Sun HT. RSC Adv 9 1696-1704 (2019)
  452. Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK. Tran KB, Kolekar S, Jabed A, Jaynes P, Shih JH, Wang Q, Flanagan JU, Rewcastle GW, Baguley BC, Shepherd PR. BMC Cancer 21 136 (2021)
  453. Efficient Hit-to-Lead Searching of Kinase Inhibitor Chemical Space via Computational Fragment Merging. Andrianov GV, Gabriel Ong WJ, Serebriiskii I, Karanicolas J. J Chem Inf Model 61 5967-5987 (2021)
  454. Establishing Human Skin Grafts in Mice as Model for Melanoma Progression. Li L, Fukunaga-Kalabis M, Herlyn M. Methods Mol Biol (2015)
  455. Fragment Discovery for the Design of Nitrogen Heterocycles as Mycobacterium tuberculosis Dihydrofolate Reductase Inhibitors. Shelke RU, Degani MS, Raju A, Ray MK, Rajan MG. Arch Pharm (Weinheim) 349 602-613 (2016)
  456. Fragment-Based Ligand Discovery Using Protein-Observed 19F NMR: A Second Semester Organic Chemistry CURE Project. Bur SK, Pomerantz WCK, Bade ML, Gee CT. J Chem Educ 98 1963-1973 (2021)
  457. High-Dose Ascorbate in Combination with Anti-PD1 Checkpoint Inhibition as Treatment Option for Malignant Melanoma. Burkard M, Niessner H, Leischner C, Piotrowsky A, Renner O, Marongiu L, Lauer UM, Busch C, Sinnberg T, Venturelli S. Cells 12 254 (2023)
  458. Hsp90 provides a platform for kinase dephosphorylation by PP5. Jaime-Garza M, Nowotny CA, Coutandin D, Wang F, Tabios M, Agard DA. Nat Commun 14 2197 (2023)
  459. Identification of Novel Natural Product Inhibitors against Matrix Metalloproteinase 9 Using Quantum Mechanical Fragment Molecular Orbital-Based Virtual Screening Methods. Lim H, Hong H, Hwang S, Kim SJ, Seo SY, No KT. Int J Mol Sci 23 4438 (2022)
  460. Identification of inactive conformation-selective interleukin-2-inducible T-cell kinase (ITK) inhibitors based on second-harmonic generation. Hantani Y, Iio K, Hantani R, Umetani K, Sato T, Young T, Connell K, Kintz S, Salafsky J. FEBS Open Bio 8 1412-1423 (2018)
  461. Improving the predictive power of xenograft and syngeneic anti-tumour studies using mice humanised for pathways of drug metabolism. Henderson CJ, McLaren AW, Kapelyukh Y, Wolf CR. F1000Res 11 1081 (2022)
  462. In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors. Żołek T, Mazurek A, Grudzinski IP. Molecules 28 5273 (2023)
  463. La génétique somatique des tumeurs solides, un incontournable à l’ère de la médecine de précision. Lehmann-Che J, Poirot B, Boyer JC, Evrard A. Therapie 72 217-230 (2017)
  464. Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells. Yeh CH, Bellon M, Wang F, Zhang H, Fu L, Nicot C. Mol Cancer 19 139 (2020)
  465. Microwave-assisted, one-pot reaction of 7-azaindoles and aldehydes: a facile route to novel di-7-azaindolylmethanes. Uddin MI, Buck JR, Schulte ML, Tang D, Saleh SA, Cheung YY, Harp J, Manning HC. Tetrahedron Lett 55 (2014)
  466. Models for prediction of (V)600(E)BRAF and melanoma cells growth inhibitory activities of pyridoimidazolones. Dutt R, Madan AK. Arch Pharm (Weinheim) 343 664-679 (2010)
  467. Molecular dynamics, MMGBSA, and docking studies of natural products conjugated to tumor-targeted peptide for targeting BRAF V600E and MERTK receptors. Lambo DJ, Lebedenko CG, McCallum PA, Banerjee IA. Mol Divers (2022)
  468. Novel oxidative stress-related prognostic biomarkers for melanoma associated with tumor metastasis. Wu X, Zhao J. Medicine (Baltimore) 100 e24866 (2021)
  469. Nucleotide stress responses in neural crest cell fate and melanoma. Sporrij A, Zon LI. Cell Cycle 20 1455-1467 (2021)
  470. Peroxisome disruption alters lipid metabolism and potentiates antitumor response with MAPK-targeted therapy in melanoma. Huang F, Cai F, Dahabieh MS, Gunawardena K, Talebi A, Dehairs J, El-Turk F, Park JY, Li M, Goncalves C, Gagnon N, Su J, LaPierre JH, Gaub P, Joyal JS, Mitchell JJ, Swinnen JV, Miller WH, Del Rincón SV. J Clin Invest 133 e166644 (2023)
  471. Predicting breast cancer drug response using a multiple-layer cell line drug response network model. Huang S, Hu P, Lakowski TM. BMC Cancer 21 648 (2021)
  472. Protein tyrosine kinase 6 regulates activation of SRC kinase. Alwanian WM, Vlajic K, Bie W, Kajdacsy-Balla A, Tyner AL. J Biol Chem 298 102584 (2022)
  473. Quantifying ERK activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling. Hamis SJ, Kapelyukh Y, McLaren A, Henderson CJ, Roland Wolf C, Chaplain MAJ. Br J Cancer 125 1552-1560 (2021)
  474. Recognition of BRAF by CDC37 and Re-Evaluation of the Activation Mechanism for the Class 2 BRAF-L597R Mutant. Bjorklund DM, Morgan RML, Oberoi J, Day KLIM, Galliou PA, Prodromou C. Biomolecules 12 905 (2022)
  475. Regulation of ERK2 activity by dynamic S-acylation. Azizi SA, Qiu T, Brookes NE, Dickinson BC. Cell Rep 42 113135 (2023)
  476. Selective CRAF Inhibition Elicits Transactivation. Morgan CW, Dale IL, Thomas AP, Hunt J, Chin JW. J Am Chem Soc 143 4600-4606 (2021)
  477. Small Molecules as Toll-like Receptor 4 Modulators Drug and In-House Computational Repurposing. Pérez-Regidor L, Guzmán-Caldentey J, Oberhauser N, Punzón C, Balogh B, Pedro JR, Falomir E, Nurisso A, Mátyus P, Menéndez JC, de Andrés B, Fresno M, Martín-Santamaría S. Biomedicines 10 2326 (2022)
  478. Solvent-Free C-3 Coupling of Azaindoles with Cyclic Imines. Belasri K, Fülöp F, Szatmári I. Molecules 24 (2019)
  479. TFEB inhibition induces melanoma shut-down by blocking the cell cycle and rewiring metabolism. Ariano C, Costanza F, Akman M, Riganti C, Corà D, Casanova E, Astanina E, Comunanza V, Bussolino F, Doronzo G. Cell Death Dis 14 314 (2023)
  480. The future of targeted therapy approaches in melanoma. Cantini LP, Meier F, Sondak VK, Smalley KS. Expert Opin Drug Discov 4 445-456 (2009)
  481. The mechanism of activation of monomeric B-Raf V600E. Maloney RC, Zhang M, Jang H, Nussinov R. Comput Struct Biotechnol J 19 3349-3363 (2021)
  482. Vemurafenib inhibits necroptosis in normal and pathological conditions as a RIPK1 antagonist. Sun M, Ma X, Mu W, Li H, Zhao X, Zhu T, Li J, Yang Y, Zhang H, Ba Q, Wang H. Cell Death Dis 14 555 (2023)


Quick links